Document:

EXCLUSIVE
LICENSE AGREEMENT

 

THIS
EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of this 29th day of March, 2017, between KOTZKER
CONSULTING LLC, a Delaware limited liability company having a business address of 20 Highview Ln, Yardley, PA 19067 (the “LICENSOR”)
and INTIVA KOTZKER PHARMACEUTICALS INC., a Colorado corporation having a business address at 3773 Cherry Creek North Drive,
Suite 575, Denver Colorado 80209 (the “LICENSEE”).

 

RECITALS

 

WHEREAS,
LICENSOR owns or has exclusively licensed all right, title and interest in certain Licensed Technology (as hereinafter defined),
for the use of cannabinoids alone or in combination with various other active pharmaceutical ingredients and/or excipients (i)
as preventative and therapeutic neuroprotectives against nerve agents and pesticides and (ii) for the treatment of diseases for
a variety of therapeutic categories;

 

WHEREAS,
LICENSOR desires to license LICENSOR’s right, title and interest in the Licensed Technology in the Licensed Field and in
the Territory (as hereinafter defined), and LICENSEE desires to secure such license in order to develop, commercialize, sell,
and license throughout the Territory products that embody or employ the Licensed Technology;

 

NOW
THEREFORE, in consideration of the premises, and the receipt of good and valuable consideration the sufficiency of which is hereby
acknowledged, the parties hereto agree as follows:

 

1.
DEFINITIONS

 

1.1
“Accounting Period” shall mean each 3 month period ending March 31, June 30, September 30, and December 31
during the term of this Agreement.

 

1.2
“Affiliate” with respect to each party shall mean any corporation or other legal entity controlling, controlled
by, or under common control with such party. The term “control” means possession, direct or indirect, of the powers
to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities,
by contract or otherwise.

 

1.3
“Approval” shall mean such approval or approvals as are necessary from an applicable Regulatory Authority for
the marketing of the Products for use in the Licensed Field in a jurisdiction within the Territory.

 

1.4
“Effective Date” shall mean the date first written above.

 

    	1

     

    

 

1.5
“FDA” shall mean the United States Food and Drug Administration and any successor thereto.

 

1.6
“First Commercial Sale” shall mean the first sale of any Licensed Product by LICENSEE, its Affiliates or Sublicensees,
but not including transfers or dispositions of Licensed Product for charitable, promotional, pre-clinical, clinical, regulatory
or governmental purposes for which LICENSEE receives no payment.

 

1.7
“License” shall have the meaning ascribed to that term in Section 2.1(a).

 

1.8
“Licensed Field” the use of cannabinoids alone or in combination with various other active pharmaceutical ingredients
and/or excipients (i) as preventative and therapeutic neuroprotectives against nerve agents and pesticides and (ii) for the treatment
of diseases for a variety of therapeutic categories.

 

1.9
“Licensed Inventions” shall mean the inventions claimed in the Licensed Patents.

 

1.10
“Licensed Know-how” shall include all technology, materials, research data, designs, formulas, process information,
manufacturing information, application information, commercialization information, clinical data, scientific data, medical data,
and any other information useful from time to time for the design, development, manufacturing, use, and/or commercialization of
the Licensed Products, whether or not eligible for protection under the patent laws of the United States or elsewhere and whether
or not any such technology, materials, information, data and the like related thereto, would be enforceable as a trade secret
or the copying of which would be enjoined or restrained by a court as constituting unfair competition, which is developed by,
or in the possession or control of, LICENSOR now or at any time during the term of this Agreement other than such information
that is independently developed by LICENSEE or its agents, as evidenced by contemporaneous written records.

 

1.11
“Licensed Patents” shall mean any and all rights arising out of or resulting from (i) the patents and patent
application set forth in Schedule 1.11 attached to this Agreement, as well as any additional patents or patent applications related
to any aspect of any Licensed Technology Improvements, Licensed Know-how, Licensed Products, and/or Licensed Technology (as herein
defined) filed prior to or during the term of this Agreement and (ii) any letters patent granted in respect of all such applications,
as well as, without limitation, any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, re-examinations,
extensions, supplementary protection certificates, confirmations, registrations, revalidations and the like, of any and all such
patents and patent applications and any international equivalents thereof.

 

1.12
“Licensed Products” shall mean any and all products, (including any and all) doses, strengths, formulations,
compositions and methods thereof containing cannabinoids alone or in combination with various other active pharmaceutical ingredients
and/or excipients for use in the Licensed Field utilizing the Licensed Technology.

 

1.13
“Licensed Technology” shall mean the aggregate of the Licensed Inventions, the Licensed Know-how, the Licensed
Products and the Licensed Patents and any other information and/or technology related to the Licensed Products and/or the design
and/or the manufacturing of the Licensed Products.

 

    	2

     

    

 

1.14
“Licensed Technology Improvements” shall have the meaning ascribed to that term in Section 2.2.

 

1.15
“Net Sales” shall mean the Gross Sales (as defined and calculated in accordance with US generally accepted
accounting principles (“GAAP”) of Licensed Products by LICENSEE or any of its Affiliates or Sublicensees (“Sellers”)
to a third party that is not an Affiliate or Sublicensee of LICENSEE (“Customer”), less applicable Sales Returns
and Allowances (as defined below), and corresponding to the definition of actual net sales used in the audited consolidated financial
statements of LICENSEE:

 

1.16
“Sales Returns and Allowances” means the sum of

 

	 	(a)	(i)
    as determined under US GAAP, trade, cash, and quantity discounts or rebates (other than price discounts granted at the time
    of invoicing and which are included in the determination of Gross Sales), credits or allowances given or made for rejection
    or return of, and for uncollectible amounts on, previously sold Licensed Products or for retroactive price reductions (including
    any types of rebates and charge-backs), (iii) taxes, duties, or other governmental charges levied on or measured by the billing
    amount for Licensed Products, and (iv) credits for allowances given or made for wastage, replacement, indigent patient, and
    any other sales programs for Licensed Products; and
	 	(b)	periodic
    adjustments of the amount determined in (a) to reflect amounts actually incurred by LICENSEE for items (i), (ii), (iii), and
    (iv) in clause (a).

 

For
purposes of determining Gross Sales, a “sale” shall not include transfers or dispositions for charitable, promotional
purposes or for pre-clinical, clinical, regulatory or governmental testing purposes for which a Seller receives no payment.

 

If
a Seller commercially uses or disposes of any Licensed Product by itself (as opposed to use or disposition of the Licensed Product
as a component of a combination of active functional elements) other than in a bona fide sale to a bona fide Customer, the Gross
Sales price of the Licensed Product for purposed of calculating Gross Sales shall be the price which would be then payable in
an arm’s length transaction with such a Customer. If a Seller commercially uses or disposes of any Licensed Product as a
component of a combination of active functional elements other than in a bona fide sale to a bona fide Customer, the Gross Sales
price of the Licensed Product for purposes of calculating Gross Sales shall be determined in accordance with the definition of
“Sales Returns and Allowances” above, using as the Gross Sales price of the combination that price which would then
be payable in an arm’s length transaction.

 

Transfer
of a Licensed Product within a Seller or between or among LICENSEE and its Affiliate and Sublicensees for sale by the transferee
shall not be considered a sale, commercial use or disposition for the purpose of the foregoing subsections; in the case of such
transfer the Gross Sales price shall be the Gross Sales price of the Licensed Product when sold to a third party by the transferee.

 

    	3

     

    

 

1.16
“Patent Right” shall mean any right, title or interest in any Licensed Patent.

 

1.17
“Regulatory Authorities” shall mean the governmental authorities responsible for regulating the development,
marketing, and/or sales of pharmaceutical products in a particular country.

 

1.18
“Seller” shall mean with respect to any sale of a Licensed Product the party responsible for such sale, where
such party may be, as applicable, LICENSEE, an Affiliate of LICENSEE or a Sublicensee.

 

1.19
“Sublicensee” shall mean any unrelated third party licensed by LICENSEE or by an Affiliate thereof to develop
or have developed, make or have made, use or have used, sell or have sold, import or have imported any Licensed Product. For the
avoidance of doubt, a wholesaler, distributor, or similar entity which purchases any Licensed Product from LICENSEE or any of
its Affiliates in a bona fide arms-length transaction, shall not be deemed to be a Sublicensee. The agreement evidencing such
sublicense shall contain relevant terms and conditions substantially similar to those in this Agreement and shall be subject to
the review and approval by LICENSOR, such approval not to be unreasonably withheld. Notwithstanding the foregoing, if LICENSEE
sublicenses to a third party who has financial wherewithal equal to or greater than the LICENSEE, the approval of LICENSEE shall
not be required.

 

1.20
“Term” shall mean the period during which this Agreement is in effect, commencing on the Effective Date and
continuing until the termination of this Agreement.

 

1.21
“Territory” shall mean the World.

 

1.22
“Valid Claim” shall mean any pending or issued claim of any patent application or patent that has not been
finally rejected or declared invalid or unenforceable by a patent office or court of competent jurisdiction in any unappealed
and unappealable decision. Notwithstanding other provisions of this Agreement, if a claim of a pending patent application within
the Licensed Patents has not issued as a claim of an issued patent within the Licensed Patents in any particular country in the
Territory, within ten (10) years after the initiation of the examination from which such claim takes priority, such pending claim
shall not be a Valid Claim in such country in the Territory for purposes of this Agreement.

 

2.
LICENSE

 

2.1
Grant of License. Subject to the provisions of this Agreement, LICENSOR hereby grants LICENSEE, including LICENSEE’s
Affiliates,

 

    	4

     

    

 

(a)
a royalty-bearing, Territory-wide license (the “License”) in the Licensed Field under the Patent Rights to the Licensed
Technology, as well as under the Licensed Patents, the Licensed Know-how, and the Licensed Technology, regardless of whether such
Licensed Patents are actually granted, to use the Licensed Know-how and Licensed Technology and to develop and have developed,
make and have made, use and have used, sell and have sold, offer for sale and have offered for sale, import and have imported,
export and have exported, any and all inventions claimed in the Licensed Patents related to the Licensed Products and/or any compounds,
chemicals, substrates, devices, tools, dies, molds or any other materials whatsoever that are useful in the development and/or
manufacturing and/or sale of the Licensed Products, and particularly including, without limitation, such license to develop and
have developed, make and have made, use and have used, sell and have sold, offer for sale and have offered for sale, import and
have imported, export and have exported Licensed Products, which license shall be exclusive even as to LICENSOR, and

 

(b)
the parties acknowledge and agree that LICENSEE is permitted to seek funding for the development of the Licensed Product, from
an Affiliate or funding source without receipt of such funds being deemed a sale or sublicense that would entitle LICENSOR to
receive any portion of the particular funding , and

 

(c)
the right to grant bona fide sublicenses to third parties, to develop and have developed, to make and have made, use and have
used, sell and have sold, import and have imported, export and have exported, Licensed Products, and to exercise all other rights
under the License; provided, however, LICENSEE shall not have the right to grant any sublicense or to transfer any of its
rights under the License unless each such sublicense or other transfer granted by LICENSEE contains terms and conditions under
which the Sublicensee or transferee will be bound in the same manner as LICENSEE is under this Agreement. A copy of the proposed
agreement shall be provided to LICENSOR prior to the execution of the Agreement.

 

2.2
Improvements. The parties acknowledge and agree that this Agreement shall apply to any and all improvements, modifications,
enhancements, or other changes to the Licensed Technology created, conceived, developed, or reduced to practice by LICENSOR during
the term of this Agreement within the Licensed Field (collectively, the “Licensed Technology Improvements”). Licensed
Technology Improvements within the Licensed Field shall be considered to be a part of the Licensed Technology and shall be licensed
to LICENSEE in accordance with the provisions of this Agreement.

 

3.
DEVELOPMENT OBLIGATIONS

 

3.1
LICENSEE’s Obligations. LICENSEE shall use its commercially reasonable efforts to develop and commercialize
the Licensed Products, and, in particular, LICENSEE will be responsible for the design, manufacturing, preclinical, clinical,
and regulatory development activities of the Licensed Products in the Territory and shall bear the costs of such activities. LICENSEE
shall be responsible for the good laboratory practices (“GLP”) and/or GLP pre-clinical toxicology studies,
good manufacturing practices (“GMP”), GMP manufacturing of the Licensed Products, including the development
of associated compounds, chemicals, substrates, devices, tools, dies, molds, and or related materials. In addition, the parties
may elect to perform non-GLP pre-clinical toxicology studies as a prelude to GLP studies. In the event that LICENSEE, after using
its commercially reasonable efforts, decides to halt or stop development, the termination provisions of Section 9 below shall
apply.

 

    	5

     

    

 

3.2
Progress Reports. At intervals no longer than every six (6) months, LICENSEE shall provide a written summary status
report of progress made toward commercialization, summarizing achievements toward commercialization in the last six months and
communicate with LICENSOR by telephone or through in-person meetings on progress made toward achieving the development and commercialization
of one or more Licensed Products.

 

3.3
Cooperation of LICENSOR. Upon execution of the Agreement, LICENSOR, in consideration of the various continuing payment
obligations of LICENSEE under Article 5 (Royalties and Milestone Payments and Equity Interest) and Article 9 (Termination), shall
provide to LICENSEE such assistance, and cooperation as shall be requested and pre-authorized in writing by LICENSEE relating
to the development and commercialization of Licensed Products, such assistance and cooperation will be provided by LICENSOR to
LICENSEE at a rate of $250/hour for consultant time and a minimum retainer of two (2) hours a month. LICENSEE shall, as it deems
necessary, separately contract with LICENSOR for consulting services regarding the design and/or manufacturing and/or commercialization
and/or general business purposes of the Licensed Products. The terms of such consulting agreement to be mutually agreed but will
include a rate of $250/hour for consultant time and a minimum retainer of two (2) hours a month and guaranteed availability of
ten (10) hours per month, being paid within 30 days of invoicing, and will be terminable by either party on sixty (60) days written
notice. All other terms to be separately negotiated between LICENSOR and LICENSEE.

 

3.4
Provision of Product in Support of Development and Sales. LICENSEE will manufacture or will have manufactured the
finished and packaged Licensed Products in support of development activities and for commercial sales.

 

4.
FILING, PROSECUTION AND MAINTENANCE OF LICENSED PATENTS

 

4.1
Responsibility. LICENSEE, at its expense, shall be responsible, and shall have sole decision-making authority, for
the preparation, filing, prosecution and maintenance of all patent applications and patents included in the Licensed Patents;
provided, however, that if the LICENSEE determines to cease the preparation, filing, prosecution or maintenance of any
patent application or patent included in the Licensed Patents, then LICENSOR, at its option and expense, shall have the right
to assume responsibility for such preparation, filing, prosecution and maintenance. Prior to abandoning any patent application,
Licensee will provide Licensor an adequate opportunity to assume such prosecution at its own expense before the application goes
abandoned.

 

4.2
Delivery of Existing Documents. With respect to each Licensed Patent, each document or a draft thereof pertaining
to the filing, prosecution, or maintenance of such Licensed Patent, including, without limitation, each patent application, office
action, response to office action, request for terminal disclaimer, request for reissue or reexamination of any patent issuing
from such application, and all other prosecution items contained in the file maintained by or for LICENSOR in respect of such
Licensed Patent in the possession of LICENSOR or its counsel at the Effective Date shall be provided to LICENSEE within fifteen
(15) days of the Effective Date and any such documents received by LICENSOR or its counsel from any patent office after the Effective
Date shall be provided within fifteen (15) days after receipt.

 

    	6

     

    

 

5.
ROYALTIES, MILESTONE PAYMENTS AND EQUITY

 

5.1
Royalties. Beginning with the First Commercial Sale in any country of any Licensed Product by LICENSEE or any of
its Affiliates or Sublicensees, LICENSEE shall pay to LICENSOR royalties in accordance with the following schedule for Licensed
Products sold by LICENSEE or its Affiliates and Sublicensees until the later to occur of (i) the expiration date of the last to
expire of the Licensed Patents; or (ii) when a competitive generic product utilizing the Licensed Technology is marketed in the
particular country in the Territory., LICENSEE will pay to LICENSOR the royalty specified below, for the manufacture, use, sale,
import or offer for sale of such Licensed Product in the country where such manufacture, use, sale, import or offer for sale of
such Licensed Product occurs, infringe a Valid Claim of any Licensed Patent or violate an exclusive marketing right granted by
any governmental agency in such country in the absence of the License granted by Article 2 or a sublicense granted under Article
2:

 

	 	(i)	Three
    percent (3%).
	 	 	 
	 	(ii)	For
    sales of Licensed Products by Sublicensees, ten percent (10%) of the total revenue received by LICENSEE, or any Affiliate
    of LICENSEE, from any other person or organization in the form of royalties, milestone payments or any other consideration
    (including the proportionate share of such non-cash consideration, for example and without limitation, stock, real property,
    and ownership interests) in respect of sublicense(s) granted by LICENSEE or any of its Affiliates under Article 2 (the “Sublicensee
    Revenue) in all countries in the Territory with the exception for Israel where LICENSOR shall receive eighteen percent (18%)
    of the Sublicensee Revenue. Notwithstanding the foregoing, in no event shall LICENSOR receive Sublicensee Revenue that is
    less cumulatively than the three percent (3%) royalty LICENSOR is entitled to if the sale had been made by LICENSEE to the
    Third Party. Additionally, regardless of LICENSEE’s sublicense to a Third Party, LICENSOR shall receive the Milestone
    Payments as set forth in Section 5.2 either from the LICENSOR or the Sublicensee; 
	 	 	 
	 	(iii)
    	To
    the extent funds received by the LICENSEE or any Affiliate, from a Sublicensee or any other source are provided for and used
    for developing Licensed Products, such funds are not considered Sublicensee Revenue under Section 5.1(iii) and such funds
    shall not be subject to any royalty payment whatsoever to LICENSOR.

 

Only
one royalty under this Section 5.1 shall be due and payable to LICENSOR by LICENSEE in respect of the sale of any Licensed Product,
regardless of the number of Valid Claims covering such Licensed Product or any other considerations. Royalty payments shall be
made within sixty (60) days after the end of the Accounting Period in which the sale is made.

 

    	7

     

    

 

5.2
Upfront and Milestone Payments. In addition to the payments provided for in Section 5.1, LICENSEE shall pay LICENSOR
the following amounts upon the occurrence of the following events:

 

	 	●	In
    consideration for access to the Licensed Patents and Licensed Technology, LICENSEE shall make the following payments to LICENSOR:
    

 

LICENSEE
shall be responsible for the patent prosecution expenses from October 1, 2016 through the earlier of the date of execution of
this Agreement or the date that LICENSEE elects to terminate negotiations with respect to this Agreement (the “Patent Expenses”).
The Patent Expenses shall not exceed $15,000. If it executes this Agreement, it shall pay one third (1/3) of the Patents Expenses
upon execution of this Agreement (the “Closing”). One Third (1/3) of the Patent Expenses shall be paid sixty (60)
days following Closing and one third (1/3) of the Patent Expenses shall be paid one hundred twenty (120) days following Closing.

 

	TIME LICENSOR SHALL RECEIVE PAYMENTS	 	PAYMENT	 
	 	 	 	 
	Upon execution of this Agreement (the “Closing”):	 	$	60,000	 
	Sixty (60) days following Closing:	 	$	60,000	 
	One hundred twenty days (120) following Closing:	 	$	60,000	 

 

	 	●	Development
    Milestone payments shall be paid by LICENSEE to LICENSOR as follows:

 

A.
for the “family” of Licensed Products for use as a preventative and therapeutic neuroprotective against nerve agents
and pesticides, LICENSEE shall make a one time payment of $500,000 as follows:

 

i.
$250,000 upon no later than thirty (30) days from acceptance of submission of the regulatory filing of the first Licensed Product
as preventative and therapeutic neuroprotectives against nerve agents and/or pesticides by the applicable Regulatory Authority.

 

ii.
$250,000 upon no later than thirty (30) days from Approval of the first Licensed Product as preventative and therapeutic for use
as neuroprotectives against nerve agents and/or pesticides by the applicable Regulatory Authority.

 

B.
for the treatment of diseases LICENSEE shall make a one-time payment of $500,000 as follows:

 

i.
$250,000 upon no later than thirty (30) days from acceptance of submission of the regulatory filing of the first Licensed Product
for treatment of a disease (i.e. a product that is not as preventative and therapeutic neuroprotectives against nerve agents and/or
pesticides) by the applicable Regulatory Authority.

 

ii.
$250,000 upon no later than thirty (30) days from Approval of the First Licensed Product for treatment of a disease by the applicable
Regulatory Authority.

 

    	8

     

    

 

5.3
Credits for Payments to Third Parties. In the event that LICENSEE and/or LICENSEE’s Affiliate is required
to pay royalties to any third parties with respect to the development or commercialization of a Licensed Product, LICENSEE will
have the right to offset such royalties against any payments owed to LICENSOR pursuant to Section 5.1, provided that no such offset
shall result in a reduction of the royalties owed to LICENSOR pursuant to Section 5.1 to an amount that is less than fifty percent
(50%) of the amount that would otherwise be due in respect of any Accounting Period.

 

5.4
Overdue Payments. The payments due under this Agreement shall, if overdue, bear interest until payment at a per
annum rate equal to the lesser of ten (10) percent and the maximum permitted by law. The payment of such interest shall not preclude
LICENSOR from exercising any other rights it may have as a consequence of the lateness of any payment.

 

5.5
Currency. All royalty payments and milestone payments under this Agreement shall be in United States Dollars. Whenever
conversion from any foreign currency shall be required, such conversion shall be at the rate of exchange thereafter published
in the Wall Street Journal for the business day closest to the end of the applicable Accounting Period.

 

5.6
Equity Interest. In consideration for entering into this Agreement, LICENSOR shall receive , within 30 calendar
days, 31,550 shares of Intiva Inc. (“Intiva”) stock. This number reflects approximately one half of one percent of
the amount of shares outstanding as of the date of this Agreement.

 

Upon
approval of the first Licensed Product, LICENSOR shall be issued US$180,000 value of Intiva’s stock based upon the share
price determined at the most recent private placement price per share with an unrelated third party, or if Intiva shares are publicly
traded the average closing price for the previous 30 days (the “Additional Stock”). For purposes of illustration,
if in the last private placement with an unrelated third party, the par share value of Intiva’s stock was equal to $5.00
per share, LICENSOR shall be issued 36,000 share of Additional Stock.

 

If
the parties determine that the development of the Licensed Product is unfeasible, as demonstrated by the failure to develop a
formulation or to establish a satisfactory regulatory pathway or a determination that the formulation to be Marketed may not be
economically viable, but LICENSEE elects to acquire an interest in the Licensed Patents, in consideration for LICENSEE continuing
to pay the cost of prosecuting the Licensed Patents and the issuance to LICENSOR of the Additional Stock referenced above which
would not otherwise be issued to LICENSOR, LICENSOR and LICENSEE shall at the time LICENSEE elects to no longer seek to develop
the Product agree that LICENSEE shall acquire a twenty five percent (25%) interest in the Licensed Patents, provided that LICENSEE
has paid LICENSOR $180,000.

 

    	9

     

    

 

6.
REPORTS AND PAYMENTS

 

6.1
Books of Accounts. LICENSEE shall keep, and shall cause each of its Affiliates and Sublicensees, if any, to keep
full and accurate books of accounts containing all particulars that may be necessary for the purpose of calculating all royalties
payable to LICENSOR. Such books of account shall be kept at their principal place of business and, with necessary supporting data
shall, during all reasonable times for the two (2) years next following the end of the calendar year to which each shall pertain,
be open for inspection at reasonable times by LICENSOR or its designee at LICENSOR’s expense for the purpose of verifying
royalty statements or compliance with this Agreement. In the event that any audit performed under this Section 6.1 reveals an
underpayment in excess of seven and one half percent (7.5%) of the total amount determined by the auditor to be due LICENSOR (the
“Underpayment”), LICENSEE shall bear the full cost of such audit and shall remit any amounts due to LICENSOR within
forty-five (45) days of receiving notice thereof from LICENSOR. LICENSOR shall have the right to audit yearly, provided however
if such audit reveals an Underpayment, LICENSOR shall thereafter have the right to audit on a semi-annual basis (with the audit
returning to a yearly basis after three (3) sequential semi-annual audits are conducted with no Underpayments discovered).

 

6.2
Quarterly Payments. In each year the amount of royalty due shall be calculated on a cash received basis on the Licensee
and Affiliates and Sublicensees books as of the end of each Accounting Period as defined in Section 1.1 of this Agreement and
shall be paid within the next sixty (60) day period following such date, every such payment to be supported by the accounting
prescribed in Section 6.3.

 

6.3
Accounting Reports. With each quarterly payment, LICENSEE shall deliver to LICENSOR a full and accurate accounting
to include at least the following information:

 

(a)
Quantity of each Licensed Product sold by LICENSEE and its Affiliate or Sublicensees (by country);

 

(b)
Inventory of each Licensed Product at end of each period held by LICENSEE and its Affiliate or Sublicensees (by country);

 

(c)
Gross Sales billed and Net Sales received by LICENSEE or any of its Affiliates or Sublicensees (“Sellers”) for the
sale of each Licensed Product with full detail of Sales Returns and Allowances used to determine the Net Sales;

 

(d)
Names and addresses of all Sublicensees of LICENSEE; and

 

(e)
Total Royalties payable to LICENSOR.

 

    	10

     

    

 

7.
INFRINGEMENT

 

7.1
Infringement of Licensed Patents. Each party shall promptly notify the other party of evidence of infringement of
a claim of a Licensed Patent by a third party. If either party shall have supplied the other party with written evidence demonstrating
prima facie infringement of a claim of a Licensed Patent in the Licensed Field by a third party, LICENSEE shall have the right
to take steps to protect the Patent Right in such claim, either upon notice from LICENSOR requesting such action, or on its own
initiative. LICENSEE shall notify LICENSOR, within three (3) months of one party providing the other with evidence of infringement,
whether LICENSEE intends to prosecute the alleged infringement. If LICENSEE notifies LICENSOR that it intends to so prosecute,
LICENSEE shall (at its expense), within three (3) months of its notice to LICENSOR either (i) cause infringement to terminate
or (ii) initiate and diligently prosecute legal proceedings against the infringer and in LICENSOR’s name if so required
by law. In the event LICENSEE notifies LICENSOR that LICENSEE does not intend to prosecute said infringement, LICENSOR may, upon
notice to LICENSEE, initiate legal proceedings against the infringer at LICENSOR’s expense. No settlement, consent judgment,
or other voluntary final disposition of the suit which invalidates or restricts the claims of such Patent Rights may be entered
into without the consent of the other party, which consent shall not be unreasonably withheld, but provided that, in the event
one party (“the Objecting Party”) withholds consent for a proposed settlement, the party proposing the settlement
may decline to support further costs of such suit or settlement discussions, and the Objecting Party shall be required to continue
such suit or settlement discussions at its own expense. LICENSEE shall indemnify LICENSOR against any order for payment that may
be made against LICENSOR in such proceedings brought by LICENSEE. LICENSOR shall indemnify LICENSEE against any order for payment
that may be made against LICENSEE in such proceedings brought by LICENSOR to the extent arising out of any proceedings which LICENSOR
brings at its own expense pursuant to Section 7.1 following LICENSEE’s decision not to prosecute any alleged infringement.

 

7.2
Cooperation. In the event one party shall initiate or carry on legal proceedings to enforce any Patent Right against
any alleged infringer, the other party shall fully cooperate with and supply all assistance reasonably requested by the party
initiating or carrying on such proceedings. The party which institutes any suit to protect or enforce a Patent Right shall have
sole control of that suit and shall bear the reasonable expenses (including legal fees) incurred by said other party in providing
such assistance and cooperating as is requested pursuant to this Section. The party initiating or carrying on such legal proceedings
shall keep the other party informed of the progress of such proceedings and said other party shall be entitled to counsel in such
proceedings but at its own expense. Any award paid by third parties as the result of such proceedings (whether by way of settlement
or otherwise) shall first be applied to reimbursement of the unreimbursed legal fees and expenses incurred by either party and
then the remainder shall be divided between the parties as follows:

 

(a)
If the amount is based on lost profits, LICENSEE shall receive an amount equal to the damages the court determines LICENSEE has
suffered as a result of the infringement less the amount of any royalties that would have been due LICENSOR on sales of Licensed
Product lost by LICENSEE as a result of the infringement had LICENSEE made such sales, and LICENSOR shall receive an amount equal
to the royalties it would have received if such sales had been made by LICENSEE, and

 

(b)
As to awards other than those based on lost profits, sixty percent (60%) to the party initiating such proceedings and forty percent
(40%) to the other party.

 

    	11

     

    

 

7.3
Infringement Actions by Third Parties. In the event that the making, selling or using of a Licensed Product in the
Licensed Field infringes the intellectual property rights of others, LICENSEE will have the first right to control any negotiation
or litigation with respect thereto; however no settlement, consent judgment or other voluntary final disposition of the infringement
allegation may be entered into without the written consent, which shall not be unreasonably withheld, of LICENSOR.

 

7.4
Further Assurances; Progress Reports. For the purpose of the proceedings referred to in this Article 7, LICENSOR
and LICENSEE shall permit the use of their names and shall execute such documents and carry out such other acts as may be necessary.
The party initiating or carrying on such legal proceedings shall keep the other party informed of the progress of such proceedings
and said other party shall be entitled to counsel in such proceedings but at its own expense, said expenses to be offset against
any damages received by the party bringing any infringement suit against a third party in accordance with Section 7.2.

 

8.
IDEMNIFICATION; REPRESENTATIONS AND WARRANTIES

 

8.1
Indemnification.

 

(a)
LICENSEE shall indemnify, defend and hold harmless LICENSOR and its directors, officers, medical and professional staff, employees,
independent contractors, and agents and their respective successors, heirs and assigns (each an “Indemnitee” under
this Section 8.1(a)), against any liability, damage, loss or expense (including reasonable attorney’s fees and expenses
of litigation) (collectively, “Losses”) incurred by or imposed upon such Indemnitees or any one of them in connection
with any claims, suits, actions, demands or judgments arising out of any theory of product liability (including, but not limited
to, actions in the form of tort, warranty, or strict liability) concerning any Licensed Product made, used or sold pursuant to
any right or license granted under this Agreement other than Losses arising out of claims of infringement of intellectual property
rights held by third parties by the practice of the Licensed Inventions, the existence of which rights constitute a breach of
the representations and warranties given by LICENSOR under Section 8.2(b) or (c).

 

(b)
LICENSOR shall indemnify, defend and hold harmless LICENSEE and its directors, officers, medical and professional staff, employees,
independent contractors, and agents and their respective successors, heirs and assigns (each an “Indemnitee” under
this Section 8.1(b)), against Losses incurred by or imposed upon such Indemnitees or any one of them in connection with any claims,
suits, actions, demands or judgments arising out of any claims of infringement of intellectual property rights held by third parties
by the practice of the Licensed Inventions, the existence of which rights constitute a breach of the representations and warranties
given by LICENSOR under Section 8.2(b) or (c); provided that in no event shall Licensor’s liability for this indemnity and
defense obligation exceed in the aggregate the total amount of Consideration actually paid to Licensor under this Agreement.

 

    	12

     

    

 

(c)
No Indemnitee under clause (a) or clause (b) of this Section 8.1 shall be entitled to any indemnification under such clause for
any Loss to the extent that such Loss is attributable to the negligent activities, reckless misconduct or intentional misconduct
of such Indemnitee.

 

(d)
Any Indemnitee under clause (a) or clause (b) of this Section 8.1 shall give the party from whom indemnification under such clause
is sought (the “Indemnitor”) prompt written notice of any Losses or discovery of fact upon which such Indemnitee intends
to base a request for indemnification under such clause, provided, however, that an Indemnitor’s obligations to such
Indemnitee under this Section 8.1 shall not be rendered inapplicable as a result of the failure by such Indemnitee to notify such
Indemnitor as required under this Section 8.1(d), unless such failure materially prejudices such Indemnitor’s ability to
take action with respect to any such Loss.

 

(e)
Each Indemnitor under this Section 8.1 agrees, at its own expense, to provide attorneys reasonably acceptable to an Indemnitee
under this Section 8.1 to defend against any actions brought or filed against such Indemnitee with respect to the subject of indemnity
contained herein, whether or not such actions are rightfully brought. Each Indemnitee under this Section 8.1 shall be entitled
to participate in, but not control, the defense of such action and to employ counsel of its own choice for such purpose; provided,
however, that such employment shall be at such Indemnitee’s own expense.

 

(f)
Each Indemnitor shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose
of any Loss, on such terms as such Indemnitor, in its sole discretion, shall deem appropriate.

 

8.2
Representations and Warranties.

 

Mutual
representations:

 

(a)
LICENSOR and LICENSEE represent and warrant to each other that: (i) it is duly organized and validly existing under the laws of
its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement
and to carry out the provisions hereof; (ii) it is duly authorized and has Board approval, in the case of LICENSEE and manager/member
approval in the case of LICENSOR, to execute and delivery this Agreement and to perform its obligations hereunder and thereunder,
and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate/company
action; (iii) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with
any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any
material law or regulations of any court, governmental body or administrative or other agency having jurisdiction over it; (iv)
neither it nor any of its Affiliates have been debarred or is subject to debarment and will not use in any capacity, in connection
with the services to be performed under this Agreement, and person who has been debarred pursuant to Section 306 of the United
States Food, Drug and Cosmetic Act or who is subject of conviction in such section..

 

LICENSOR
represents to LICENSEE that:

 

    	13

     

    

 

(a)
To the best of LICENSOR’s actual knowledge with respect solely to its Licensed Technology, as of the Effective Date there
is no fact or circumstance that would prevent the use of the Licensed Technology to develop Licensed Products that could be Approved
by a Regulatory Authority.

 

(b)
LICENSOR is the sole and exclusive owner of all right, title and interest in and to the Patent Rights to the Licensed Patents
originally listed on Schedule 1.11 and such rights, and all other rights granted to LICENSEE under the License existing as of
the date hereof, are not subject to any encumbrance, lien or claim of ownership by any third party. LICENSOR has obtained all
necessary assignments and made all appropriate filings with respect thereto in order to secure its sole and exclusive ownership
rights in and to such Patent Rights, and all other rights granted to LICENSEE as of the date hereof. During the term of this Agreement,
LICENSOR shall not knowingly take any action that would encumber the rights granted to LICENSEE hereunder.

 

(c)
Except for the grant by LICENSOR to LICENSEE of the License and other rights in Article 2, which relate solely to the Licensed
Product, LICENSOR has not, directly or indirectly, expressly or by implication, by action or omission or otherwise (i) assigned,
transferred or conveyed any right, title or interest in or to the Patent Rights in the Licensed Patents and/or any other rights
granted to LICENSEE under the License, (ii) granted any license or other right, title or interest in or to the Patent Rights in
the Licensed Patents and/or any other rights granted to LICENSEE under the License, or (iii) agreed to or is otherwise bound by
any covenant not to sue for any infringement, misuse or otherwise with respect to the Patent Rights in the Licensed Patents and/or
any other rights granted to LICENSEE under the License.

 

(d)
To the best of LICENSOR’s knowledge, there is no actual or threatened infringement by a third party of the Patent Rights
in the Licensed Patents.

 

8.3
Limitation on Damages and Disclaimer. WITH THE EXCEPTION FOR INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OF SUCH
PARTY, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, COLLATERAL, EXEMPLARY, PUNITIVE, OR CONSEQUENTIAL
DAMAGES, INCLUDING LOSS OF INCOME, PROFIT OR SAVINGS, OF ANY PARTY, INCLUDING THIRD PARTIES, REGARDLESS OF THE FORM OF THE ACTION
OR THE THEORY OF RECOVERY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

OTHER
THAN WARRANTIES SET FORTH HEREIN, EACH PARTY MAKES NO WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK,
SOFTWARE, TRADE SECRET, TANGIBLE RESEARCH PROPERTY, INFORMATION OR DATA LICENSED OR OTHERWISE PROVIDED TO THE OTHER PARTY HEREUNDER
AND HEREBY DISCLAIMS THE SAME.

 

    	14

     

    

 

8.4
Insurance. Licensee will maintain insurance in amounts and areas of coverage that are considered commercially reasonable
in this industry. The Licensee will obtain such insurance coverages and will provide each other with proof of such insurance coverage.

 

9.
TERMINATION

 

9.1
Upon Expiration of Patent Rights and Exclusive Marketing Rights.

 

(a)
Unless otherwise terminated as provided for in this Agreement, the License and other rights granted to LICENSEE in Article 2 will
continue on a country by country and Licensed Product by Licensed Product basis, and shall expire in each country for each Licensed
Product sold in that country when the manufacture, use, sale, import or offer for sale of such Licensed Product in said country
on the later to occur of (i) the expiration date of the last to expire of the Licensed Patents or when a competitor generic product
utilizing the Licensed Technology is marketed in the particular country in the Territory. In such an event, the License, with
respect to such country and such Licensed Product, will be automatically converted to a fully paid-up royalty–free perpetual
license that grants LICENSEE the same bundle of rights as the License, including all the rights under Section 2.1(b) to grant
sublicenses.

 

(b)
Notwithstanding the foregoing, in the event LICENSOR and/or LICENSEE are unable to obtain patent protection for a Licensed Product
in any particular country, the License shall be in effect with respect to such Licensed Product in such country, with LICENSEE
paying LICENSOR fees equal to the normal royalty rates and subject to the conditions specified in Section 5.1, for a period of
ten (10) years after the First Commercial Sale of said Licensed Product in such country, so long as generic competition (where
“generic competition” exists when a product having the same active pharmaceutical ingredient as a Licensed Product,
and utilizing the Licensed Technology, is marketed by a competitor in the same country as said Licensed Product) is absent with
regard to said Licensed Product, as consideration for the right to use the Licensed Know How and the unpatented Licensed technology
as well as any continuing technical and informational marketing support from LICENSOR. At the earlier of the expiration of the
ten (10) year period or when generic competition begins with regard to said Licensed Product in a country for which there is no
Licensed Patent, the License, with respect to such country and Licensed Product, will convert to the fully paid-up royalty-free
perpetual license described in Section 9.1(a), including all the rights under Section 2.1(b) to grant sublicenses.

 

(c)
If LICENSEE was able to operate for some period under the protections of patent rights with regard to a particular Licensed Product
in a particular country, then, for so long as generic competition is absent with regards to said Licensed Product in said particular
country and upon the expiration of such patent rights and/or exclusive marketing rights, as described in Section 9.1(a), LICENSEE
shall continue to pay LICENSOR fees equal to the normal royalty rates and subject to the conditions specified in Section 5.1 for
the right to use the Licensed Know How and the unpatented Licensed Technology as well as any continuing technical and informational
marketing support from LICENSOR.

 

9.2
Upon Default, Generally. If either party shall fail to faithfully perform any of its obligations under this Agreement,
the non-defaulting party may give written notice of the default to the defaulting party. Unless such default is corrected within
sixty (60) days after such notice, the notifying party may terminate this Agreement upon thirty (30) days prior written notice;
provided, however, in the event that prior to the expiration of any such sixty (60) day period, such breaching party has
in good faith commenced to use commercially reasonable efforts to remedy such breach and the completion of such remedy, due to
reasons beyond the control of such breaching party, requires more than sixty (60) days to complete, then such sixty (60) day period
shall be extended for so long as such breaching party is continuing in good faith to use commercially reasonable efforts to remedy
such breach.

 

    	15

     

    

 

9.3
If Commercially Unfeasible. LICENSEE may terminate this Agreement on thirty (30) days written notice to Licensor,
without penalty and at any time, if LICENSEE, at its sole discretion, determines that further development, manufacture, and/or
sales of the Licensed Products will be commercially unfeasible.

 

9.4
Effect on Sublicenses. In the event that the License granted to LICENSEE under this Agreement is terminated, any
sublicense under such License granted prior to termination of said License shall remain in full force and effect, provided that:

 

(a)
the Sublicensee is not then in breach of its sublicense agreement;

 

(b)
the Sublicensee agrees to be bound to LICENSOR as the licensor under the terms and conditions of this Agreement, as modified by
the provisions of this Section 9.4;

 

(c)
LICENSOR shall have the right to receive any payments payable to LICENSEE under such sublicense agreement to the extent that they
are reasonably and equitably attributable to such Sublicensee’s right under such sublicense to use and exploit Patent Rights
in the Licensed Patents and other rights granted in the License;

 

(d)
the Sublicensee agrees to be bound by the development and commercialization obligations of LICENSEE pursuant to Article 3 (whether
set by the parties or by arbitration) in the field and territory of the sublicense;

 

(e)
LICENSOR has the right to terminate such sublicense upon thirty (30) days prior written notice to LICENSEE and such Sublicensee
in the event of any material breach of the obligation to make the payments described in clause (c) of this Section 9.3, unless
such breach is cured prior to the expiration of such thirty (30) day period, and shall further have the right to terminate such
sublicense in the event of Sublicensee’s failure to meet its development obligations pursuant to clause (d) hereof; and

 

(f)
LICENSOR shall not assume, and shall not be responsible to each Sublicensee for, any representations, warranties or obligations
of LICENSEE to such Sublicensee, other than to permit such Sublicensee to exercise any rights to the Patent Rights in the Licensed
Patents and other rights under the License that are granted under such sublicense agreement consistent with the terms of this
Agreement.

 

9.5
Payments. Upon termination of the License granted hereunder, LICENSEE shall pay LICENSOR all royalties, milestone
payments and any other amounts due or accrued up to and including the date of termination and (ii) for twelve (12) months following
the date of termination, the sale of Licensed Products manufactured prior to the termination date, if LICENSEE and LICENSOR separately
agree to conduct such sales.

 

    	16

     

    

 

10.
CONFIDENTIAL INFORMATION

 

10.1
Definitions. Each party receiving information (the “Receiving Party”) disclosed to it by the other party
(the “Disclosing Party”) acknowledges that by reason of its relationship to the Disclosing Party hereunder, between
the parties, will have, or has had, access to certain information and materials, including the terms of this Agreement and information
concerning the Disclosing Party’s business, plans, technology, products and/or services that are confidential and of substantial
value to the Disclosing Party (“Confidential Information”).

 

10.2
Obligation to Protect Confidential Information. Each Receiving Party agrees that it shall (i) take every reasonable
precaution to protect the confidentiality of Disclosing Party’s Confidential Information from unauthorized access or use
and (ii) not use the Disclosing Party’s Confidential Information in any way for the Receiving Party’s own account
or the account of any third party except for the purposes of performing its obligations under this Agreement. Upon termination
of this Agreement and at the request of the Disclosing Party, the Receiving Party will return to Disclosing Party all of the Disclosing
Party’s Confidential Information in its possession or within its control or destroy such Confidential Information and certify
in writing to the Disclosing Party that all such information has been destroyed; however, Receiving Party shall have the right
to retain one (1) copy of the Disclosing Party’s Confidential Information solely for the purpose of determining Receiving
Party’s obligations under this Agreement.

 

10.3
Exclusions. Confidential Information does not include any information that the Receiving Party can demonstrate by
written records: (a) was known to the Receiving Party prior to its disclosure by the Disclosing Party; (b) was independently developed
by the Receiving Party without use of or reference to the Disclosing Party’s Confidential Information; (c) was or becomes
publicly known through no wrongful act of the Receiving Party; (d) was rightfully received from a third party whom the Receiving
Party had reasonable grounds to believe was authorized to make such disclosure without restriction; or (e) has been approved for
public release by the Disclosing Party’s prior written authorization. Further, if the Receiving Party is required to disclose
Confidential Information pursuant to a subpoena, court order or other similar process (“Court Order”), it is agreed
that the Receiving Party shall provide the Disclosing Party with notice of such request(s), to the extent that such notice is
legally permissible, so that the Disclosing Party may seek an appropriate protective order. In the event that the Disclosing Party
is not successful in obtaining a protective order and the Receiving Party is compelled to disclose the Confidential Information,
the Receiving Party may disclose such information solely in accordance with and for the limited purpose of compliance with the
Court Order without liability hereunder.

 

    	17

     

    

 

10.4
Disclosures Required by Law. In addition, either party may disclose, on a confidential basis, the existence and
terms of this Agreement to existing or potential investors in such party, or in connection with a private or public offering of
such party’s securities. Furthermore, either party may disclose, on a confidential and need-to-know basis, the existence
and terms of this Agreement and the proposed terms of this Agreement to its counsel, accountants, directors and other similar
advisors (the “Representatives”). The foregoing shall not, however, operate or grant either party any rights under
any patents, trade secrets, copyrights, or any other proprietary rights of the other party.

 

10.5
Remedies. The parties acknowledge that money damages would be both incalculable and an insufficient remedy for any
breach of the confidentiality provisions of this Agreement, and that any such breach would cause the other party irreparable harm.
Accordingly, the parties hereto agree that in the event of any such breach or threatened breach hereof by a party or by its respective
Representatives, the other party to this Agreement shall be entitled, in addition to any other available remedies at law, to seek
equitable relief, including injunctive relief and specific performance without the posting of any bond or other security.

 

11.
MISCELLANEOUS

 

11.1
Entire Agreement. This Agreement constitutes the entire understanding between the parties with respect to the subject
matter hereof.

 

11.2
Notices. All notices and other communications required or permitted under this Agreement shall be in writing and
shall be sent by registered or certified mail (return receipt requested and postage prepaid), or delivered by hand, by messenger
or by a recognized overnight delivery service, addressed to each party as follows:

 

if
to LICENSOR:

 

KOTZKER
CONSULTING LLC

20
Highview Ln.

Yardley,
PA 19067

Attn:
Joseph Morgan, M.D.

 

With
a copy to:

Gerard
P. Norton

Fox
Rothschild LLP

997
Lenox Drive, Building 3

Lawrenceville,
NJ

08543

 

if
to LICENSEE:

 

INTIVA
KOTZKER PHARMACEUTICALS INC.

3773
Cherry Creek North Drive

Suite
575

Denver
Colorado 80209

Attn:
Jeffery Friedland

 

    	18

     

    

 

With
a copy to:

Robert
I. Goldfarb

Robert
I. Goldfarb P.A.

6100
Hollywood Blvd, Suite 207

Hollywood,
FL 33024

 

Each
such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if
sent by registered or certified mail, the earlier of receipt and five (5) business days after dispatch, and (ii) if delivered
in person, by messenger, or by overnight courier, on the business day delivered.

 

11.3
Amendments; Waivers. This Agreement may be amended or any of its terms or conditions may be waived only by a written
instrument executed by the parties or, in the case of a waiver, by the party waiving compliance. The failure of either party at
any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce
the same. No waiver by either party of any condition shall be deemed as a further or continuing waiver of such condition or term
or of any other condition or term.

 

11.4
Assignment, Successors. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the
parties hereto and their respective successors and permitted assigns; provided that this Agreement shall not be assignable by
LICENSOR without LICENSEE’s written consent (which consent shall not be unreasonably withheld, delayed or conditioned) except
for the right to receive royalties or other payments payable herein, and further provided that LICENSEE may, with the consent
of LICENSOR (which consent shall not be unreasonably withheld, delayed or conditioned), transfer its interest or any part thereof
under this Agreement to a wholly-owned subsidiary of LICENSEE or to any assignee or purchaser of the portion of its business associated
with the manufacture and sale of Licensed Product, so long as such transferee assumes and agrees to be bound by the provisions
of this Agreement.

 

11.5
Force Majeure. Any delays in or failures of performance by either party under this Agreement shall not be considered
a breach of this Agreement if and to the extent caused by occurrences beyond the reasonable control of the party affected, including
but not limited to: acts of God, acts, regulations, or laws of any government, strikes or the concerted acts of workers, fires,
floods, explosions, riots, wars, rebellion, and sabotage. Any time for performance hereunder shall be extended by the actual time
of delay caused by such occurrence; provided, however, that either party shall have the right to terminate this Agreement
if any such extension endures for more than twelve (12) consecutive months.

 

11.6
Publicity. Neither party shall use the name of the other party or any staff member, officer, employee or student
of the other party or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document
employed to obtain funds or financing without the prior written approval of the party or individual whose name is to be used.
Notwithstanding the foregoing, the parties agree that LICENSEE may disclose to its Representatives, investors and potential investors
that Dr. Joseph Morgan is the physician and scientist who conceived of the concepts and is reflected as the inventor in the patent
applications.

 

    	19

     

    

 

11.7
Governing Law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of
the State of Colorado, without regard to its choice of law principles.

 

11.8
Alternative Dispute Resolution. For any and all claims, disputes, or controversies arising under, out of, or in
connection with this Agreement, except issues relating to the validity, construction or effect of any Patent Right, which the
parties shall be unable to resolve within sixty (60) days, then either party may after such sixty (60) day period advise the other
party of its intent to pursue such claim, dispute, or controversy in Alternative Dispute Resolution (ADR) in a writing which describes
in reasonable detail the nature of such dispute. By not later than five (5) business days after the recipient has received such
notice of dispute, each party shall have selected for itself a representative who shall have the authority to bind such party
and shall additionally have advised the other party in writing of the name and title of such representative. By not later than
ten (10) business days after the date of such notice of dispute, such representatives shall agree upon a third party, which is
in the business of providing Alternative Dispute Resolution (ADR) services (hereinafter, “ADR Provider”) and shall
schedule a date with such ADR Provider to engage in ADR. Thereafter, the representatives of the parties shall engage in good faith
in an ADR process under the auspices of the selected ADR Provider. If within the aforesaid ten (10) business days after the date
of the notice of dispute the representatives of the parties have not been able to agree upon an ADR Provider and schedule a date
to engage in ADR, or if they have not been able to resolve the dispute within thirty (30) business days after the conclusion of
ADR, the parties shall have the right to pursue any other remedies legally available to resolve such dispute in either the state
or federal courts of Colorado, to whose jurisdiction for such purposes each of LICENSOR and LICENSEE hereby irrevocably consents
and submits. Notwithstanding the foregoing, nothing in this Section 11.8 shall be construed to waive any rights or timely performance
of any obligations existing under this Agreement.

 

11.9
Severability. If any provision(s) of this Agreement are or become invalid, are ruled illegal by any court of competent
jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the term thereof,
it is the intention of the parties that the remainder of this Agreement shall not be affected thereby. It is further the intention
of the parties that in lieu of each such provision which is invalid, illegal or unenforceable, there be substituted or added as
part of this Agreement a provision which shall be as similar as possible in economic and business objectives as intended by the
parties to such invalid, illegal or enforceable provision, but shall be valid, legal and enforceable.

 

11.10
Independent Contractors. It is expressly agreed that LICENSOR, on the one hand, and LICENSEE, on the other hand,
shall be independent contractors and that the relationship between the two parties shall not constitute a partnership, joint venture
or agency. Neither LICENSOR, on the one hand, nor LICENSEE, on the other hand, shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall be binding on the other, without the prior written
consent of the other party to do so. All persons employed by a party shall be employees of such party and not of the other party
and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such party.

 

11.11
Survival. Sections 5, 6, 8, 9 10 and 11 shall survive the expiration or termination of this Agreement.

 

11.12
Counterparts. This Agreement may be executed in two counterparts, each of which shall be enforceable against the
party actually executing such counterpart, and both of which together shall constitute one instrument.

 

11.13
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not
considered in construing or interpreting this Agreement.

 

THE
PARTIES have duly executed this Agreement as of the date first shown above written.

[signature
page follows]

 

    	20

     

    

 

[signature page to Exclusive License Agreement]

 

	LICENSOR:
    	 	LICENSEE:
	KOTZKER
    CONSULTING LLC	 	INTIVA
    KOTZKER PHARMACEUTICALS INC.
	 	 	 	 	 
	BY:	              	 	BY:	                             
	NAME: 	 	 	NAME:
    	 
	TITLE: 	 	 	TITLE:	 

 

    	21

     

    

 

Schedule
1.11

 

Patents
and Patent Applications

 

	Country	 	Status	 	Application
    #	 	Filing
    Date	 	Publication
    #	 	Publication
    Date
	Canada	 	Pending	 	2,895,805	 	18-Jun-2015	 	 	 	 
	European
    Patent Office	 	Published	 	13866227.5	 	17-Jul-2015	 	2934512	 	28-Oct-2015
	Israel	 	Pending	 	238946	 	21-May-2015	 	 	 	 
	India	 	Pending	 	1877/KOLNP/2015	 	16-Jun-2015	 	 	 	 
	United
    States	 	Published	 	14/649,951	 	05-Jun-2015	 	2015-0313868	 	05-Nov-2015
	Untiled
    States	 	Expired	 	61/738,782	 	18-Dec-2012	 	 	 	 
	PCT	 	Expired	 	PCT/US13/76223	 	18-Dec-2013	 	2014/100231	 	26-Jun-2014

 

    	22INTIVA
BIOPHARMA INC.

 

2018
EQUITY INCENTIVE PLAN

 

    	 

     

    

 

Table
of Contents

 

	1.	PURPOSE	1
	2.	SHARES
    SUBJECT TO THE PLAN	1
	2.1.	Number
    of Shares Available	1
	2.2.	Lapsed,
    Returned Awards	1
	2.3.	Minimum
    Share Reserve	1
	2.4.	Automatic
    Share Reserve Increase	1
	2.5.	Limitations	2
	2.6.	Adjustment
    of Shares	2
	3.	ELIGIBILITY	2
	4.	ADMINISTRATION	2
	4.1.	Committee
    Composition; Authority	2
	4.2.	Committee
    Interpretation and Discretion	4
	4.3.	Section
    162(m) of the Code and Section 16 of the Exchange Act	4
	4.4.	Documentation	5
	4.5.	Foreign
    Award Recipients	5
	5.	OPTIONS	5
	5.1.	Option
    Grant	5
	5.2.	Date
    of Grant	5
	5.3.	Exercise
    Period	6
	5.4.	Exercise
    Price	6
	5.5.	Method
    of Exercise	6
	5.6.	Termination
    of Service	6
	5.7.	Limitations
    on Exercise	7
	5.8.	Limitations
    on ISOs	7
	5.9.	Modification,
    Extension or Renewal	8
	5.10.	No
    Disqualification	8
	6.	RESTRICTED
    STOCK AWARDS	8
	6.1.	Restricted
    Stock Purchase Agreement	8
	6.2.	Purchase
    Price	8
	6.3.	Terms
    of Restricted Stock Awards	8
	6.4.	Termination
    of Service	9
	7.	STOCK
    BONUS AWARDS	9
	7.1.	Terms
    of Stock Bonus Awards	9

 

    	i

     

    

 

	7.2.	Form
    of Payment to Participant	9
	7.3.	Termination
    of Service	9
	8.	STOCK
    APPRECIATION RIGHTS	9
	8.1.	Terms
    of SARs	9
	8.2.	Exercise
    Period and Expiration Date	10
	8.3.	Form
    of Settlement	10
	8.4.	Termination
    of Service	10
	9.	PAYMENT
    FOR SHARE PURCHASES	10
	10.	GRANTS
    TO NON-EMPLOYEE DIRECTORS	11
	11.	WITHHOLDING
    TAXES	11
	11.1.	Withholding
    Generally	11
	11.2.	Stock
    Withholding	11
	12.	TRANSFERABILITY	11
	12.1.	Transfer
    Generally	11
	12.2.	Award
    Transfer Program	12
	13.	PRIVILEGES
    OF STOCK OWNERSHIP; RESTRICTIONS ON SHARES	12
	13.1.	Voting
    and Dividends	12
	13.2.	Restrictions
    on Shares	13
	14.	CERTIFICATES	13
	15.	ESCROW;
    PLEDGE OF SHARES	13
	16.	REPRICING;
    EXCHANGE AND BUYOUT OF AWARDS	13
	17.	SECURITIES
    LAW AND OTHER REGULATORY COMPLIANCE	13
	18.	NO
    OBLIGATION TO EMPLOY	14
	19.	CORPORATE
    TRANSACTIONS	14
	19.1.	Assumption
    or Replacement of Awards by Successor	14
	19.2.	Assumption
    of Awards by Intiva	14
	19.3.	Non-Employee
    Directors’ Awards	15
	20.	ADOPTION
    AND STOCKHOLDER APPROVAL	15
	21.	TERM
    OF PLAN/GOVERNING LAW	15
	22.	AMENDMENT
    OR TERMINATION OF PLAN	15
	23.	NONEXCLUSIVITY
    OF THE PLAN	15
	24.	INSIDER
    TRADING POLICY	15
	25.	ALL
    AWARDS SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT POLICY	16
	26.	DEFINITIONS	16
    

 

    	ii

     

    

 

INTIVA
BIOPHARMA INC. 

 

2018
EQUITY INCENTIVE PLAN 

 

1.
PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present
and potential contributions are important to the success of Intiva, and any Parents, Subsidiaries and Affiliates that exist now
or in the future, by offering them an opportunity to participate in Intiva’s future performance through the grant of Awards.
Capitalized terms not defined elsewhere in the text are defined in Section 26.

 

2.
SHARES SUBJECT TO THE PLAN.

 

2.1.
Number of Shares Available. Subject to Sections 2.6 and 19 and any other applicable provisions hereof, the total number
of Shares reserved and available for grant and issuance pursuant to this Plan as of the date of adoption of the Plan by the Board,
is Eight Million (8,000,000) Shares, plus (a) any reserved shares not issued or subject to outstanding grants under Intiva’s
2017 Stock Incentive Plan (the “Prior Plan”) on the Effective Date (as defined below), and (b) shares
that are subject to awards granted under the Prior Plan that cease to be subject to such awards by forfeiture or otherwise after
the Effective Date.

 

2.2.
Lapsed, Returned Awards. Shares subject to Awards, and Shares issued under the Plan under any Award, will again be available
for grant and issuance in connection with subsequent Awards under this Plan to the extent such Shares: (a) are subject to issuance
upon exercise of an Option or SAR granted under this Plan but which cease to be subject to the Option or SAR for any reason other
than exercise of the Option or SAR; (b) are subject to Awards granted under this Plan that are forfeited or are repurchased by
Intiva at the original issue price; (c) are subject to Awards granted under this Plan that otherwise terminate without such Shares
being issued; or (d) are surrendered pursuant to an Exchange Program. To the extent an Award under the Plan is paid out in cash
rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan.
Shares used to pay the exercise price of an Award or withheld to satisfy the tax withholding obligations related to an Award will
become available for future grant or sale under the Plan. For the avoidance of doubt, Shares that otherwise become available for
grant and issuance because of the provisions of this Section 2.2 will not include Shares subject to Awards that initially
became available because of the substitution clause in Section 19.2 hereof.

 

2.3.
Minimum Share Reserve. At all times Intiva will reserve and keep available a sufficient number of Shares as will be required
to satisfy the requirements of all outstanding Awards granted under this Plan.

 

2.4.
Automatic Share Reserve Increase. The number of Shares available for grant and issuance under the Plan will be increased on
July 1, of each of the first ten (10) calendar years during the term of the Plan, by the lesser of (a) fifteen percent (15%) of
the number of Shares issued during the most recently completed fiscal year or (b) such number of Shares determined by the Board.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 1

     

    

 

2.5.
Limitations. No more than eighty percent (80%) Shares will be issued pursuant to the exercise of ISOs.

 

2.6.
Adjustment of Shares. If the number of outstanding Shares is changed by a stock dividend, extraordinary dividends or distributions
(whether in cash, shares or other property, other than a regular cash dividend) recapitalization, stock split, reverse stock split,
subdivision, combination, consolidation, reclassification, spin-off or similar change in the capital structure of Intiva, without
consideration, then (a) the number and class of Shares reserved for issuance and future grant under the Plan set forth in Section
2.1, including shares reserved under sub-clauses (a) and (b) of Section 2.1, (b) the Exercise Prices of and number
and class of Shares subject to outstanding Options and SARs, (c) the number and class of Shares subject to other outstanding Awards,
(d) the maximum number and class of Shares that may be issued as ISOs set forth in Section 2.5, (e) the maximum number
and class of Shares that may be issued to an individual or to a new Employee in any one calendar year set forth in Section
3 and (f) the number and class of Shares that may be granted as Awards to Non-Employee Directors as set forth in Section
10, will be proportionately adjusted, subject to any required action by the Board or the stockholders of Intiva and in compliance
with applicable securities laws; provided that fractions of a Share will not be issued.

 

If,
by reason of an adjustment pursuant to this Section 2.6, a Participant’s Award Agreement or other agreement related
to any Award or the Shares subject to such Award covers additional or different shares of stock or securities, then such additional
or different shares, and the Award Agreement or such other agreement in respect thereof, will be subject to all of the terms,
conditions and restrictions which were applicable to the Award or the Shares subject to such Award prior to such adjustment.

 

3.
ELIGIBILITY. ISOs may be granted only to Employees. All other Awards may be granted to Employees, Consultants, Directors and
Non-Employee Directors; provided such Consultants, Directors and Non-Employee Directors render bona fide services not in
connection with the offer and sale of securities in a capital-raising transaction. No Participant will be eligible to receive
an Award or Awards for more than one million (1,000,000) Shares in any calendar year under this Plan except that new Employees
of Intiva or of a Parent or Subsidiary of Intiva are eligible to be granted up to a maximum of an Award or Awards for two million
(2,000,000) Shares in the calendar year in which they commence their employment.

 

4.
ADMINISTRATION.

 

4.1.
Committee Composition; Authority. This Plan will be administered by the Committee or by the Board acting as the Committee.
Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the Committee will have
full power to implement and carry out this Plan, except, however, the Board will establish the terms for the grant of an Award
to Non-Employee Directors. The Committee will have the authority to:

 

(a)
construe and interpret this Plan, any Award Agreement and any other agreement or document executed pursuant to this Plan;

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 2

     

    

 

(b)
prescribe, amend and rescind rules and regulations relating to this Plan or any Award;

 

(c)
select persons to receive Awards;

 

(d)
determine the form and terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such
terms and conditions include, but are not limited to, the Exercise Price, the time or times when Awards may vest and be exercised
(which may be based on performance criteria) or settled, any vesting acceleration or waiver of forfeiture restrictions, the method
to satisfy tax withholding obligations or any other tax liability legally due and any restriction or limitation regarding any
Award or the Shares relating thereto, based in each case on such factors as the Committee will determine;

 

(e)
determine the number of Shares or other consideration subject to Awards;

 

(f)
determine the Fair Market Value in good faith and interpret the applicable provisions of this Plan and the definition of Fair
Market Value in connection with circumstances that impact the Fair Market Value, if necessary;

 

(g)
determine whether Awards will be granted singly, in combination with, in tandem with, in replacement of, or as alternatives to,
other Awards under this Plan or any other incentive or compensation plan of Intiva or any Parent, Subsidiary or Affiliate;

 

(h)
grant waivers of Plan or Award conditions;

 

(i)
determine the vesting, exercisability and payment of Awards;

 

(j)
correct any defect, supply any omission or reconcile any inconsistency in this Plan, any Award or any Award Agreement;

 

(k)
determine whether an Award has been vested and/or earned;

 

(l)
determine the terms and conditions of any, and to institute any Exchange Program;

 

(m)
reduce or waive any criteria with respect to Performance Factors;

 

(n)
adjust Performance Factors to take into account changes in law and accounting or tax rules as the Committee deems necessary or
appropriate to reflect the impact of extraordinary or unusual items, events or circumstances to avoid windfalls or hardships provided
that such adjustments are consistent with the regulations promulgated under Section 162(m) of the Code with respect to persons
whose compensation is subject to Section 162(m) of the Code;

 

(o)
adopt rules and/or procedures (including the adoption of any subplan under this Plan) relating to the operation and administration
of the Plan to accommodate requirements of local law and procedures outside of the United States;

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 3

     

    

 

(p)
make all other determinations necessary or advisable for the administration of this Plan; and

 

(q)
delegate any of the foregoing to one or more executive officers pursuant to a specific delegation as permitted by applicable law,
including Section 157(c) of the Delaware General Corporation Law.

 

4.2.
Committee Interpretation and Discretion. Any determination made by the Committee with respect to any Award will be made in
its sole discretion at the time of grant of the Award or, unless in contravention of any express term of the Plan or Award, at
any later time, and such determination will be final and binding on Intiva and all persons having an interest in any Award under
the Plan. Any dispute regarding the interpretation of the Plan or any Award Agreement will be submitted by the Participant or
Intiva to the Committee for review. The resolution of such a dispute by the Committee will be final and binding on Intiva and
the Participant. The Committee may delegate to one or more executive officers the authority to review and resolve disputes with
respect to Awards held by Participants who are not Insiders, and such resolution will be final and binding on Intiva and the Participant.

 

4.3.
Section 162(m) of the Code and Section 16 of the Exchange Act. When necessary or desirable for an Award to qualify as “performance-based
compensation” under Section 162(m) of the Code, the Committee administering the Plan in accordance with the requirements
of Rule 16b-3 and Section 162(m) of the Code will consist of at least two individuals, each of whom qualifies as (a) a Non-Employee
Director under Rule 16b-3, and (b) an “outside director” pursuant to Code Section 162(m) and the regulations issued
thereunder. At least two (or a majority if more than two then serve on the Committee) such “outside directors” will
approve the grant of such Award and timely determine (as applicable) the Performance Period and any Performance Factors upon which
vesting or settlement of any portion of such Award is to be subject. When required by Section 162(m) of the Code, prior to settlement
of any such Award at least two (or a majority if more than two then serve on the Committee) such “outside directors”
then serving on the Committee will determine and certify in writing the extent to which such Performance Factors have been timely
achieved and the extent to which the Shares subject to such Award have thereby been earned. Awards granted to Participants who
are subject to Section 16 of the Exchange Act must be approved by two or more “non-employee directors” (as defined
in the regulations promulgated under Section 16 of the Exchange Act). With respect to Participants whose compensation is subject
to Section 162(m) of the Code, and provided that such adjustments are consistent with the regulations promulgated under Section
162(m) of the Code, the Committee may adjust the performance goals to account for changes in law and accounting and to make such
adjustments as the Committee deems necessary or appropriate to reflect the impact of extraordinary or unusual items, events or
circumstances to avoid windfalls or hardships, including without limitation (a) restructurings, discontinued operations, extraordinary
items, and other unusual or non-recurring charges, (b) an event either not directly related to the operations of Intiva or not
within the reasonable control of Intiva’s management, or (c) a change in accounting standards required by generally accepted
accounting principles.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 4

     

    

 

4.4.
Documentation. The Award Agreement for a given Award, the Plan and any other documents may be delivered to, and accepted by,
a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements.

 

4.5.
Foreign Award Recipients. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws and
practices in other countries in which Intiva, its Subsidiaries and Affiliates operate or have Employees or other individuals eligible
for Awards, the Committee, in its sole discretion, will have the power and authority to: (a) determine which Subsidiaries and
Affiliates will be covered by the Plan; (b) determine which individuals outside the United States are eligible to participate
in the Plan, which may include individuals who provide services to Intiva, Subsidiary or Affiliate under an agreement with a foreign
nation or agency; (c) modify the terms and conditions of any Award granted to individuals outside the United States or foreign
nationals to comply with applicable foreign laws, policies, customs and practices; (d) establish subplans and modify exercise
procedures and other terms and procedures, to the extent the Committee determines such actions to be necessary or advisable (and
such subplans and/or modifications will be attached to this Plan as appendices); provided, however, that no such subplans
and/or modifications will increase the share limitations contained in Section 2.1 hereof; and (e) take any action, before
or after an Award is made, that the Committee determines to be necessary or advisable to obtain approval or comply with any local
governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Committee may not take any actions hereunder,
and no Awards will be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code,
or any other applicable United States governing statute or law.

 

5.
OPTIONS. An Option is the right but not the obligation to purchase a Share, subject to certain conditions, if applicable.
The Committee may grant Options to eligible Employees, Consultants and Directors and will determine whether such Options will
be Incentive Stock Options within the meaning of the Code (“ISOs”) or Nonqualified Stock Options (“NSOs”),
the number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may vest and
be exercised, and all other terms and conditions of the Option, subject to the following terms of this section.

 

5.1.
Option Grant. Each Option granted under this Plan will identify the Option as an ISO or an NSO. An Option may be, but need
not be, awarded upon satisfaction of such Performance Factors during any Performance Period as are set out in advance in the Participant’s
individual Award Agreement. If the Option is being earned upon the satisfaction of Performance Factors, then the Committee will:
(a) determine the nature, length and starting date of any Performance Period for each Option; and (b) select from among the Performance
Factors to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously
with respect to Options that are subject to different performance goals and other criteria.

 

5.2.
Date of Grant. The date of grant of an Option will be the date on which the Committee makes the determination to grant such
Option, or a specified future date. The Award Agreement and a copy of this Plan will be delivered to the Participant within a
reasonable time after the granting of the Option.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 5

     

    

 

5.3.
Exercise Period. Options may be vested and exercisable within the times or upon the conditions as set forth in the Award Agreement
governing such Option; provided, however, that no Option will be exercisable after the expiration of ten (10) years from
the date the Option is granted; and provided further that no ISO granted to a person who, at the time the ISO is granted,
directly or by attribution owns more than ten percent (10%) of the total combined voting power of all classes of stock of Intiva
or of any Parent or Subsidiary (“Ten Percent Stockholder”) will be exercisable after the expiration
of five (5) years from the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time
or from time to time, periodically or otherwise, in such number of Shares or percentage of Shares as the Committee determines.

 

5.4.
Exercise Price. The Exercise Price of an Option will be determined by the Committee when the Option is granted; provided
that: (a) the Exercise Price of an Option will be not less than one hundred percent (100%) of the Fair Market Value of the
Shares on the date of grant and (b) the Exercise Price of any ISO granted to a Ten Percent Stockholder will not be less than one
hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased may be
made in accordance with Section 9 and the Award Agreement and in accordance with any procedures established by Intiva.

 

5.5.
Method of Exercise. Any Option granted hereunder will be vested and exercisable according to the terms of the Plan and at
such times and under such conditions as determined by the Committee and set forth in the Award Agreement. An Option may not be
exercised for a fraction of a Share. An Option will be deemed exercised when Intiva receives: (a) notice of exercise (in such
form as the Committee may specify from time to time) from the person entitled to exercise the Option (and/or via electronic execution
through the authorized third party administrator), and (b) full payment for the Shares with respect to which the Option is exercised
(together with applicable withholding taxes). Full payment may consist of any consideration and method of payment authorized by
the Committee and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the
name of the Participant. Until the Shares are issued (as evidenced by the appropriate entry on the books of Intiva or of a duly
authorized transfer agent of Intiva), no right to vote or receive dividends or any other rights as a stockholder will exist with
respect to the Shares, notwithstanding the exercise of the Option. Intiva will issue (or cause to be issued) such Shares promptly
after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to
the date the Shares are issued, except as provided in Section 2.6 of the Plan. Exercising an Option in any manner will
decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number
of Shares as to which the Option is exercised.

 

5.6.
Termination of Service. If the Participant’s Service terminates for any reason except for Cause or the Participant’s
death or Disability, then the Participant may exercise such Participant’s Options only to the extent that such Options would
have been exercisable by the Participant on the date Participant’s Service terminates no later than three (3) months after
the date Participant’s Service terminates (or such shorter time period not less than thirty (30) days or longer time period
as may be determined by the Committee, with any exercise beyond three (3) months after the date Participant’s Service terminates
deemed to be the exercise of an NSO), but in any event no later than the expiration date of the Options.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 6

     

    

 

(a)
Death. If the Participant’s Service terminates because of the Participant’s death (or the Participant dies
within three (3) months after Participant’s Service terminates other than for Cause or because of the Participant’s
Disability), then the Participant’s Options may be exercised only to the extent that such Options would have been exercisable
by the Participant on the date Participant’s Service terminates and must be exercised by the Participant’s legal representative,
or authorized assignee, no later than eighteen (18) months after the date Participant’s Service terminates (or such shorter
time period not less than six (6) months or longer time period as may be determined by the Committee), but in any event no later
than the expiration date of the Options.

 

(b)
Disability. If the Participant’s Service terminates because of the Participant’s Disability, then the Participant’s
Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant’s
Service terminates and must be exercised by the Participant (or the Participant’s legal representative or authorized assignee)
no later than twelve (12) months after the date Participant’s Service terminates (or such shorter time period not less than
six (6) months or longer time period as may be determined by the Committee, with any exercise beyond (a) three (3) months after
the date Participant’s Service terminates when the termination of Service is for a Disability that is not a “permanent
and total disability” as defined in Section 22(e)(3) of the Code, or (b) twelve (12) months after the date Participant’s
Service terminates when the termination of Service is for a Disability that is a “permanent and total disability”
as defined in Section 22(e)(3) of the Code, deemed to be exercise of an NSO), but in any event no later than the expiration date
of the Options.

 

(c)
Cause. If the Participant’s Service terminates for Cause, then Participant’s Options will expire on such Participant’s
date of termination of Service, or at such later time and on such conditions as are determined by the Committee, but in any event
no later than the expiration date of the Options. Unless otherwise provided in an employment agreement or Award Agreement, Cause
will have the meaning set forth in the Plan.

 

5.7.
Limitations on Exercise. The Committee may specify a minimum number of Shares that may be purchased on any exercise of an
Option, provided that such minimum number will not prevent any Participant from exercising the Option for the full number of Shares
for which it is then exercisable.

 

5.8.
Limitations on ISOs. With respect to Awards granted as ISOs, to the extent that the aggregate Fair Market Value of the Shares
with respect to which such ISOs are exercisable for the first time by the Participant during any calendar year (under all plans
of Intiva and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as NSOs.
For purposes of this Section 5.8, ISOs will be taken into account in the order in which they were granted. The Fair Market
Value of the Shares will be determined as of the time the Option with respect to such Shares is granted. In the event that the
Code or the regulations promulgated thereunder are amended after the Effective Date to provide for a different limit on the Fair
Market Value of Shares permitted to be subject to ISOs, such different limit will be automatically incorporated herein and will
apply to any Options granted after the effective date of such amendment.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 7

     

    

 

5.9.
Modification, Extension or Renewal. The Committee may modify, extend or renew outstanding Options and authorize the grant
of new Options in substitution therefor, provided that any such action may not, without the written consent of a Participant,
impair any of such Participant’s rights under any Option previously granted. Any outstanding ISO that is modified, extended,
renewed or otherwise altered will be treated in accordance with Section 424(h) of the Code. Subject to Section 16 of this
Plan, by written notice to affected Participants, the Committee may reduce the Exercise Price of outstanding Options without the
consent of such Participants; provided, however, that the Exercise Price may not be reduced below the Fair Market Value
on the date the action is taken to reduce the Exercise Price.

 

5.10.
No Disqualification. Notwithstanding any other provision in this Plan, no term of this Plan relating to ISOs will be interpreted,
amended or altered, nor will any discretion or authority granted under this Plan be exercised, so as to disqualify this Plan under
Section 422 of the Code or, without the consent of the Participant affected, to disqualify any ISO under Section 422 of the Code.

 

6.
RESTRICTED STOCK AWARDS. A Restricted Stock Award is an offer by Intiva to sell to an eligible Employee, Consultant, or Director
Shares that are subject to restrictions (“Restricted Stock”). The Committee will determine to whom an
offer will be made, the number of Shares the Participant may purchase, the Purchase Price, the restrictions under which the Shares
will be subject and all other terms and conditions of the Restricted Stock Award, subject to the Plan.

 

6.1.
Restricted Stock Purchase Agreement. All purchases under a Restricted Stock Award will be evidenced by an Award Agreement.
Except as may otherwise be provided in an Award Agreement, a Participant accepts a Restricted Stock Award by signing and delivering
to Intiva an Award Agreement with full payment of the Purchase Price, within thirty (30) days from the date the Award Agreement
was delivered to the Participant. If the Participant does not accept such Award within thirty (30) days, then the offer of such
Restricted Stock Award will terminate, unless the Committee determines otherwise.

 

6.2.
Purchase Price. The Purchase Price for a Restricted Stock Award will be determined by the Committee and may be less than Fair
Market Value on the date the Restricted Stock Award is granted. Payment of the Purchase Price must be made in accordance with
Section 9 of the Plan, and the Award Agreement and in accordance with any procedures established by Intiva.

 

6.3.
Terms of Restricted Stock Awards. Restricted Stock Awards will be subject to such restrictions as the Committee may impose
or are required by law. These restrictions may be based on completion of a specified number of years of service with Intiva or
upon completion of Performance Factors, if any, during any Performance Period as set out in advance in the Participant’s
Award Agreement. Prior to the grant of a Restricted Stock Award, the Committee will: (a) determine the nature, length and starting
date of any Performance Period for the Restricted Stock Award; (b) select from among the Performance Factors to be used to measure
performance goals, if any; and (c) determine the number of Shares that may be awarded to the Participant. Performance Periods
may overlap and a Participant may participate simultaneously with respect to Restricted Stock Awards that are subject to different
Performance Periods and having different performance goals and other criteria.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 8

     

    

 

6.4.
Termination of Service. Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such date
Participant’s Service terminates (unless determined otherwise by the Committee).

 

7.
STOCK BONUS AWARDS. A Stock Bonus Award is an award to an eligible Employee, Consultant, or Director of Shares for Services
to be rendered or for past Services already rendered to Intiva or any Parent, Subsidiary or Affiliate. All Stock Bonus Awards
will be made pursuant to an Award Agreement. No payment from the Participant will be required for Shares awarded pursuant to a
Stock Bonus Award.

 

7.1.
Terms of Stock Bonus Awards. The Committee will determine the number of Shares to be awarded to the Participant under a Stock
Bonus Award and any restrictions thereon. These restrictions may be based upon completion of a specified number of years of service
with Intiva or upon satisfaction of performance goals based on Performance Factors during any Performance Period as set out in
advance in the Participant’s Stock Bonus Agreement. Prior to the grant of any Stock Bonus Award the Committee will: (a)
determine the nature, length and starting date of any Performance Period for the Stock Bonus Award; (b) select from among the
Performance Factors to be used to measure performance goals; and (c) determine the number of Shares that may be awarded to the
Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Stock Bonus Awards
that are subject to different Performance Periods and different performance goals and other criteria.

 

7.2.
Form of Payment to Participant. Payment may be made in the form of cash, whole Shares, or a combination thereof, based on
the Fair Market Value of the Shares earned under a Stock Bonus Award on the date of payment, as determined in the sole discretion
of the Committee.

 

7.3.
Termination of Service. Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such date
Participant’s Service terminates (unless determined otherwise by the Committee).

 

8.
STOCK APPRECIATION RIGHTS. A Stock Appreciation Right (“SAR”) is an award to an eligible Employee,
Consultant, or Director that may be settled in cash, or Shares (which may consist of Restricted Stock), having a value equal to
(a) the difference between the Fair Market Value on the date of exercise over the Exercise Price multiplied by (b) the number
of Shares with respect to which the SAR is being settled (subject to any maximum number of Shares that may be issuable as specified
in an Award Agreement). All SARs will be made pursuant to an Award Agreement.

 

8.1.
Terms of SARs. The Committee will determine the terms of each SAR including, without limitation: (a) the number of Shares
subject to the SAR; (b) the Exercise Price and the time or times during which the SAR may be settled; (c) the consideration to
be distributed on settlement of the SAR; and (d) the effect of the Participant’s termination of Service on each SAR. The
Exercise Price of the SAR will be determined by the Committee when the SAR is granted, and may not be less than Fair Market Value
of the Shares on the date of grant. A SAR may be awarded upon satisfaction of Performance Factors, if any, during any Performance
Period as are set out in advance in the Participant’s individual Award Agreement. If the SAR is being earned upon the satisfaction
of Performance Factors, then the Committee will: (x) determine the nature, length and starting date of any Performance Period
for each SAR; and (y) select from among the Performance Factors to be used to measure the performance, if any. Performance Periods
may overlap and Participants may participate simultaneously with respect to SARs that are subject to different Performance Factors
and other criteria.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 9

     

    

 

8.2.
Exercise Period and Expiration Date. A SAR will be exercisable within the times or upon the occurrence of events determined
by the Committee and set forth in the Award Agreement governing such SAR. The SAR Agreement will set forth the expiration date;
provided that no SAR will be exercisable after the expiration of ten (10) years from the date the SAR is granted. The Committee
may also provide for SARs to become exercisable at one time or from time to time, periodically or otherwise (including, without
limitation, upon the attainment during a Performance Period of performance goals based on Performance Factors), in such number
of Shares or percentage of the Shares subject to the SAR as the Committee determines. Except as may be set forth in the Participant’s
Award Agreement, vesting ceases on the date Participant’s Service terminates (unless determined otherwise by the Committee).
Notwithstanding the foregoing, the rules of Section 5.6 also will apply to SARs.

 

8.3.
Form of Settlement. Upon exercise of a SAR, a Participant will be entitled to receive payment from Intiva in an amount determined
by multiplying (a) the difference between the Fair Market Value of a Share on the date of exercise over the Exercise Price; times
(b) the number of Shares with respect to which the SAR is exercised. At the discretion of the Committee, the payment from Intiva
for the SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. The portion of a SAR being
settled may be paid currently or on a deferred basis with such interest or Dividend Equivalent Right, if any, as the Committee
determines, provided that the terms of the SAR and any deferral satisfy the requirements of Section 409A of the Code.

 

8.4.
Termination of Service. Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such date
Participant’s Service terminates (unless determined otherwise by the Committee).

 

9.
PAYMENT FOR SHARE PURCHASES. Payment from a Participant for Shares purchased pursuant to this Plan may be made in cash or
by check or, where expressly approved for the Participant by the Committee and where permitted by law (and to the extent not otherwise
set forth in the applicable Award Agreement):

 

(a)
by cancellation of indebtedness of Intiva to the Participant;

 

(b)
by surrender of shares of Intiva held by the Participant that have a Fair Market Value on the date of surrender equal to the aggregate
exercise price of the Shares as to which said Award will be exercised or settled;

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 10

     

    

 

(c)
by waiver of compensation due or accrued to the Participant for services rendered or to be rendered to Intiva or a Parent or Subsidiary;

 

(d)
by consideration received by Intiva pursuant to a broker-assisted or other form of cashless exercise program implemented by Intiva
in connection with the Plan;

 

(e)
by any combination of the foregoing; or

 

(f)
by any other method of payment as is permitted by applicable law.

 

10.
GRANTS TO NON-EMPLOYEE DIRECTORS. [RESERVED]

 

11.
WITHHOLDING TAXES.

 

11.1.
Withholding Generally. Whenever Shares are to be issued in satisfaction of Awards granted under this Plan or a tax event occurs,
Intiva may require the Participant to remit to Intiva, or to the Parent, Subsidiary or Affiliate, as applicable, employing the
Participant, an amount sufficient to satisfy applicable U.S. federal, state, local and international tax or any other tax or social
insurance liability (the “Tax-Related Items”) legally due from the Participant prior to the delivery
of Shares pursuant to exercise or settlement of any Award. Whenever payments in satisfaction of Awards granted under this Plan
are to be made in cash, such payment will be net of an amount sufficient to satisfy applicable withholding obligations for Tax-Related
Items. Unless otherwise determined by the Committee, the Fair Market Value of the Shares will be determined as of the date that
the taxes are required to be withheld and such Shares will be valued based on the value of the actual trade or, if there is none,
the Fair Market Value of the Shares as of the previous trading day.

 

11.2.
Stock Withholding. The Committee, or its delegate(s), as permitted by applicable law, in its sole discretion and pursuant
to such procedures as it may specify from time to time and to limitations of local law, may require or permit a Participant to
satisfy such Tax Related Items legally due from the Participant, in whole or in part by (without limitation) (a) paying cash,
(b) having Intiva withhold otherwise deliverable cash or Shares having a Fair Market Value equal to the Tax-Related Items to be
withheld, (c) delivering to Intiva already-owned shares having a Fair Market Value equal to the Tax-Related Items to be withheld
or (d) withholding from the proceeds of the sale of otherwise deliverable Shares acquired pursuant to an Award either through
a voluntary sale or through a mandatory sale arranged by Intiva. Intiva may withhold or account for these Tax-Related Items by
considering applicable statutory withholding rates or other applicable withholding rates, including up to the maximum permissible
statutory tax rate for the applicable tax jurisdiction, to the extent consistent with applicable laws.

 

12.
TRANSFERABILITY.

 

12.1.
Transfer Generally. Unless determined otherwise by the Committee or pursuant to Section 12.2, an Award may not be sold,
pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution.
If the Committee makes an Award transferable, including, without limitation, by instrument to an inter vivos or testamentary trust
in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift or by domestic relations
order to a Permitted Transferee, such Award will contain such additional terms and conditions as the Committee deems appropriate.
All Awards will be exercisable: (a) during the Participant’s lifetime only by (i) the Participant, or (ii) the Participant’s
guardian or legal representative; (b) after the Participant’s death, by the legal representative of the Participant’s
heirs or legatees; and (c) in the case of all awards except ISOs, by a Permitted Transferee.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 11

     

    

 

12.2.
Award Transfer Program. Notwithstanding any contrary provision of the Plan, the Committee will have all discretion and authority
to determine and implement the terms and conditions of any Award Transfer Program instituted pursuant to this Section 12.2
and will have the authority to amend the terms of any Award participating, or otherwise eligible to participate in, the Award
Transfer Program, including (but not limited to) the authority to (a) amend (including to extend) the expiration date, post-termination
exercise period and/or forfeiture conditions of any such Award, (b) amend or remove any provisions of the Award relating to the
Award holder’s continued Service to Intiva or any Parent, Subsidiary or Affiliate, (c) amend the permissible payment methods
with respect to the exercise or purchase of any such Award, (d) amend the adjustments to be implemented in the event of changes
in the capitalization and other similar events with respect to such Award, and (e) make such other changes to the terms of such
Award as the Committee deems necessary or appropriate in its sole discretion.

 

13.
PRIVILEGES OF STOCK OWNERSHIP; RESTRICTIONS ON SHARES.

 

13.1.
Voting and Dividends. No Participant will have any of the rights of a stockholder with respect to any Shares until the Shares
are issued to the Participant, except for any Dividend Equivalent Rights permitted by an applicable Award Agreement. Any Dividend
Equivalent Rights will be subject to the same vesting or performance conditions as the underlying Award. In addition, the Committee
may provide that any Dividend Equivalent Rights permitted by an applicable Award Agreement will be deemed to have been reinvested
in additional Shares or otherwise reinvested. After Shares are issued to the Participant, the Participant will be a stockholder
and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or
other distributions made or paid with respect to such Shares; provided, that if such Shares are Restricted Stock, then
any new, additional or different securities the Participant may become entitled to receive with respect to such Shares by virtue
of a stock dividend, stock split or any other change in the corporate or capital structure of Intiva will be subject to the same
restrictions as the Restricted Stock; provided, further, that the Participant will have no right to such stock dividends
or stock distributions with respect to Unvested Shares, and any such dividends or stock distributions will be accrued and paid
only at such time, if any, as such Unvested Shares become vested Shares. The Committee, in its discretion, may provide in the
Award Agreement evidencing any Award that the Participant will be entitled to Dividend Equivalent Rights with respect to the payment
of cash dividends on Shares underlying an Award during the period beginning on the date the Award is granted and ending, with
respect to each Share subject to the Award, on the earlier of the date on which the Award is exercised or settled or the date
on which it is forfeited provided, that no Dividend Equivalent Right will be paid with respect to the Unvested Shares,
and such dividends or stock distributions will be accrued and paid only at such time, if any, as such Unvested Shares become vested
Shares. Such Dividend Equivalent Rights, if any, will be credited to the Participant in the form of additional whole Shares as
of the date of payment of such cash dividends on Shares.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 12

     

    

 

13.2.
Restrictions on Shares. At the discretion of the Committee, Intiva may reserve to itself and/or its assignee(s) a right to
repurchase (a “Right of Repurchase”) a portion of any or all Unvested Shares held by a Participant following
such Participant’s termination of Service at any time within ninety (90) days (or such longer or shorter time determined
by the Committee) after the later of the date Participant’s Service terminates and the date the Participant purchases Shares
under this Plan, for cash and/or cancellation of purchase money indebtedness, at the Participant’s Purchase Price or Exercise
Price, as the case may be.

 

14.
CERTIFICATES. All Shares or other securities whether or not certificated, delivered under this Plan will be subject to such
stock transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions
under any applicable U.S. federal, state or foreign securities law, or any rules, regulations and other requirements of the SEC
or any stock exchange or automated quotation system upon which the Shares may be listed or quoted and any non-U.S. exchange controls
or securities law restrictions to which the Shares are subject.

 

15.
ESCROW; PLEDGE OF SHARES. To enforce any restrictions on a Participant’s Shares, the Committee may require the Participant
to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee,
appropriately endorsed in blank, with Intiva or an agent designated by Intiva to hold in escrow until such restrictions have lapsed
or terminated, and the Committee may cause a legend or legends referencing such restrictions to be placed on the certificates.
Any Participant who is permitted to execute a promissory note as partial or full consideration for the purchase of Shares under
this Plan will be required to pledge and deposit with Intiva all or part of the Shares so purchased as collateral to secure the
payment of the Participant’s obligation to Intiva under the promissory note; provided, however, that the Committee
may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event, Intiva
will have full recourse against the Participant under the promissory note notwithstanding any pledge of the Participant’s
Shares or other collateral. In connection with any pledge of the Shares, the Participant will be required to execute and deliver
a written pledge agreement in such form as the Committee will from time to time approve. The Shares purchased with the promissory
note may be released from the pledge on a pro rata basis as the promissory note is paid.

 

16.
REPRICING; EXCHANGE AND BUYOUT OF AWARDS. Without prior stockholder approval the Committee may (a) reprice Options or SARs
(and where such repricing is a reduction in the Exercise Price of outstanding Options or SARs, the consent of the affected Participants
is not required provided written notice is provided to them, notwithstanding any adverse tax consequences to them arising from
the repricing), and (b) with the consent of the respective Participants (unless not required pursuant to Section 5.9 of
the Plan), pay cash or issue new Awards in exchange for the surrender and cancellation of any, or all, outstanding Awards.

 

17.
SECURITIES LAW AND OTHER REGULATORY COMPLIANCE. An Award will not be effective unless such Award is in compliance with all
applicable U.S. and foreign federal and state securities, exchange control or other laws, rules and regulations of any governmental
body, and the requirements of any stock exchange or automated quotation system upon which the Shares may then be listed or quoted,
as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any
other provision in this Plan, Intiva will have no obligation to issue or deliver certificates for Shares under this Plan prior
to: (a) obtaining any approvals from governmental agencies that Intiva determines are necessary or advisable; and/or (b) completion
of any registration or other qualification of such Shares under any state or federal or foreign law or ruling of any governmental
body that Intiva determines to be necessary or advisable. Intiva will be under no obligation to register the Shares with the SEC
or to effect compliance with the registration, qualification or listing requirements of any foreign or state securities laws,
exchange control laws, stock exchange or automated quotation system, and Intiva will have no liability for any inability or failure
to do so.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 13

     

    

 

18.
NO OBLIGATION TO EMPLOY. Nothing in this Plan or any Award granted under this Plan will confer or be deemed to confer on any
Participant any right to continue in the employ of, or to continue any other relationship with, Intiva or any Parent, Subsidiary
or Affiliate or limit in any way the right of Intiva or any Parent, Subsidiary or Affiliate to terminate Participant’s employment
or other relationship at any time.

 

19.
CORPORATE TRANSACTIONS.

 

19.1.
Assumption or Replacement of Awards by Successor. In the event of a Corporate Transaction any or all outstanding Awards may
be assumed or replaced by the successor corporation, which assumption or replacement will be binding on all Participants. In the
alternative, the successor corporation may substitute equivalent Awards or provide substantially similar consideration to Participants
as was provided to stockholders (after taking into account the existing provisions of the Awards). The successor corporation may
also issue, in place of outstanding Shares of Intiva held by the Participant, substantially similar shares or other property subject
to repurchase restrictions no less favorable to the Participant. In the event such successor or acquiring corporation (if any)
refuses to assume, convert, replace or substitute Awards, as provided above, pursuant to a Corporate Transaction, then notwithstanding
any other provision in this Plan to the contrary, such Awards will have their vesting accelerate as to all shares subject to such
Award (and any applicable right of repurchase fully lapse) immediately prior to the Corporate Transaction. In addition, in the
event such successor or acquiring corporation (if any) refuses to assume, convert, replace or substitute Awards, as provided above,
pursuant to a Corporate Transaction, the Committee will notify the Participant in writing or electronically that such Award will
be exercisable for a period of time determined by the Committee in its sole discretion, and such Award will terminate upon the
expiration of such period. Awards need not be treated similarly in a Corporate Transaction.

 

19.2.
Assumption of Awards by Intiva. Intiva, from time to time, also may substitute or assume outstanding awards granted by another
company, whether in connection with an acquisition of such other company or otherwise, by either; (a) granting an Award under
this Plan in substitution of such other company’s award; or (b) assuming such award as if it had been granted under this
Plan if the terms of such assumed award could be applied to an Award granted under this Plan. Such substitution or assumption
will be permissible if the holder of the substituted or assumed award would have been eligible to be granted an Award under this
Plan if the other company had applied the rules of this Plan to such grant. In the event Intiva assumes an award granted by another
company, the terms and conditions of such award will remain unchanged (except that the Purchase Price or the Exercise Price,
as the case may be, and the number and nature of Shares issuable upon exercise or settlement of any such Award will be adjusted
appropriately pursuant to Section 424(a) of the Code). In the event Intiva elects to grant a new Option in substitution rather
than assuming an existing option, such new Option may be granted with a similarly adjusted Exercise Price. Substitute Awards will
not reduce the number of Shares authorized for grant under the Plan or authorized for grant to a Participant in a calendar year.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 14

     

    

 

19.3.
Non-Employee Directors’ Awards. Notwithstanding any provision to the contrary herein, in the event of a Corporate Transaction,
the vesting of all Awards granted to Non-Employee Directors will accelerate and such Awards will become exercisable (as applicable)
in full prior to the consummation of such event at such times and on such conditions as the Committee determines.

 

20.
ADOPTION AND STOCKHOLDER APPROVAL. This Plan will be submitted for the approval of Intiva’s stockholders, consistent
with applicable laws, within twelve (12) months before or after the date this Plan is adopted by the Board.

 

21.
TERM OF PLAN/GOVERNING LAW. Unless earlier terminated as provided herein, this Plan will become effective on the Effective
Date and will terminate ten (10) years from the date this Plan is adopted by the Board. This Plan and all Awards granted hereunder
will be governed by and construed in accordance with the laws of the State of Delaware (excluding its conflict of laws rules).

 

22.
AMENDMENT OR TERMINATION OF PLAN. The Board may at any time terminate or amend this Plan in any respect, including, without
limitation, amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan; provided, however,
that the Board will not, without the approval of the stockholders of Intiva, amend this Plan in any manner that requires such
stockholder approval; provided further, that a Participant’s Award will be governed by the version of this Plan then
in effect at the time such Award was granted. No termination or amendment of the Plan will affect any then-outstanding Award unless
expressly provided by the Committee. In any event, no termination or amendment of the Plan or any outstanding Award may adversely
affect any then outstanding Award without the consent of the Participant, unless such termination or amendment is necessary to
comply with applicable law, regulation or rule.

 

23.
NONEXCLUSIVITY OF THE PLAN. Neither the adoption of this Plan by the Board, the submission of this Plan to the stockholders
of Intiva for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board
to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting of stock
awards and bonuses otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only
in specific cases.

 

24.
INSIDER TRADING POLICY. Each Participant who receives an Award will comply with any policy adopted by Intiva from time to
time covering transactions in Intiva’s securities by Employees, officers and/or directors of Intiva, as well as with any
applicable insider trading or market abuse laws to which the Participant may be subject.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 15

     

    

 

25.
ALL AWARDS SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT POLICY. All Awards, subject to applicable law, will be subject to clawback
or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term
of Participant’s employment or other service with Intiva that is applicable to executive officers, employees, directors
or other service providers of Intiva, and in addition to any other remedies available under such policy and applicable law, may
require the cancellation of outstanding Awards and the recoupment of any gains realized with respect to Awards.

 

26.
DEFINITIONS. As used in this Plan, and except as elsewhere defined herein, the following terms will have the following meanings:

 

26.1.
“Affiliate” means (i) any entity that, directly or indirectly, is controlled by, controls or is
under common control with, Intiva and (ii) any entity in which Intiva has a significant equity interest, in either case as determined
by the Committee, whether now or hereafter existing.

 

26.2.
“Award” means any award under the Plan, including any Option, Restricted Stock, Stock Bonus, or
Stock Appreciation Right.

 

26.3.
“Award Agreement” means, with respect to each Award, the written or electronic agreement between
Intiva and the Participant setting forth the terms and conditions of the Award, and country-specific appendix thereto for grants
to non-U.S. Participants, which will be in substantially a form (which need not be the same for each Participant) that the Committee
(or in the case of Award agreements that are not used for Insiders, the Committee’s delegate(s)) has from time to time approved,
and will comply with and be subject to the terms and conditions of this Plan.

 

26.4.
“Award Transfer Program” means any program instituted by the Committee which would permit Participants
the opportunity to transfer any outstanding Awards to a financial institution or other person or entity approved by the Committee.

 

26.5.
“Board” means the Board of Directors of Intiva.

 

26.6.
“Cause” means a determination by Intiva that the Participant has committed an act or acts constituting
any of the following: (i) dishonesty, fraud, misconduct or negligence in connection with Intiva duties, (ii) unauthorized disclosure
or use of Intiva’s confidential or proprietary information, (iii) misappropriation of a business opportunity of Intiva,
(iv) materially aiding a Intiva competitor, (v) a felony conviction; or (vi) failure or refusal to attend to the duties or obligations
of the Participant’s position, or to comply with Intiva’s rules, policies or procedures. The determination as to whether
a Participant is being terminated for Cause will be made in good faith by Intiva and will be final and binding on the Participant.
The foregoing definition does not in any way limit Intiva’s ability to terminate a Participant’s employment or consulting
relationship at any time as provided in Section 18 above, and the term “Intiva” will be interpreted to include
any Subsidiary or Parent, as appropriate. Notwithstanding the foregoing, the foregoing definition of “Cause” may,
in part or in whole, be modified or replaced in each individual employment agreement, Award Agreement or other applicable agreement
with any Participant, provided that such document supersedes the definition provided in this Section 26.6.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 16

     

    

 

26.7.
“Code” means the United States Internal Revenue Code of 1986, as amended, and the regulations promulgated
thereunder.

 

26.8.
“Committee” means the Compensation Committee of the Board or those persons to whom administration
of the Plan, or part of the Plan, has been delegated as permitted by law.

 

26.9.
“Common Stock” means the common stock of Intiva.

 

26.10.
“Consultant” means any natural person, including an advisor or independent contractor, engaged by
Intiva or a Parent, Subsidiary or Affiliate to render services to such entity.

 

26.11.
“Corporate Transaction” means the occurrence of any of the following events: (a) any “Person”
(as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined
in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of Intiva representing more than fifty percent (50%)
of the total voting power represented by Intiva’s then-outstanding voting securities; provided, however, that for
purposes of this subclause (a) the acquisition of additional securities by any one Person who is considered to own more than fifty
percent (50%) of the total voting power of the securities of Intiva will not be considered a Corporate Transaction; (b) the consummation
of the sale or disposition by Intiva of all or substantially all of Intiva’s assets; (c) the consummation of a merger or
consolidation of Intiva with any other corporation, other than a merger or consolidation which would result in the voting securities
of Intiva outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted
into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented
by the voting securities of Intiva or such surviving entity or its parent outstanding immediately after such merger or consolidation;
(d) any other transaction which qualifies as a “corporate transaction” under Section 424(a) of the Code wherein the
stockholders of Intiva give up all of their equity interest in Intiva (except for the acquisition, sale or transfer of all or
substantially all of the outstanding shares of capital stock of Intiva) or (e) a change in the effective control of Intiva that
occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by members of the Board
whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or
election. For purpose of this subclause (e), if any Person is considered to be in effective control of Intiva, the acquisition
of additional control of Intiva by the same Person will not be considered a Corporate Transaction. For purposes of this definition,
Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation,
purchase or acquisition of stock, or similar business transaction with Intiva. Notwithstanding the foregoing, to the extent that
any amount constituting deferred compensation (as defined in Section 409A of the Code) would become payable under this Plan by
reason of a Corporate Transaction, such amount will become payable only if the event constituting a Corporate Transaction would
also qualify as a change in ownership or effective control of Intiva or a change in the ownership of a substantial portion of
the assets of Intiva, each as defined within the meaning of Code Section 409A, as it has been and may be amended from time to
time, and any proposed or final Treasury Regulations and IRS guidance that has been promulgated or may be promulgated thereunder
from time to time.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 17

     

    

 

26.12.
“Director” means a member of the Board.

 

26.13.
“Disability” means in the case of incentive stock options, total and permanent disability as defined
in Section 22(e)(3) of the Code and in the case of other Awards, that the Participant is unable to engage in any substantial gainful
activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can
be expected to last for a continuous period of not less than 12 months.

 

26.14.
“Dividend Equivalent Right” means the right of a Participant, granted at the discretion of the Committee
or as otherwise provided by the Plan, to receive a credit for the account of such Participant in an amount equal to the cash,
stock or other property dividends in amounts equal equivalent to cash, stock or other property dividends for each Share represented
by an Award held by such Participant.

 

26.15.
“Effective Date” means March __, 2018.

 

26.16.
“Employee” means any person, including Officers and Directors, providing services as an employee
to Intiva or any Parent, Subsidiary or Affiliate. Neither service as a Director nor payment of a director’s fee by Intiva
will be sufficient to constitute “employment” by Intiva.

 

26.17.
“Exchange Act” means the United States Securities Exchange Act of 1934, as amended.

 

26.18.
“Exchange Program” means a program pursuant to which (a) outstanding Awards are surrendered, cancelled
or exchanged for cash, the same type of Award or a different Award (or combination thereof) or (b) the exercise price of an outstanding
Award is increased or reduced.

 

26.19.
“Exercise Price” means, with respect to an Option, the price at which a holder may purchase the
Shares issuable upon exercise of an Option and with respect to a SAR, the price at which the SAR is granted to the holder thereof.

 

26.20.
“Fair Market Value” means, as of any date, the value of a share of Intiva’s Common Stock determined
as follows:

 

(a)
if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of
determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported
in The Wall Street Journal or such other source as the Committee deems reliable;

 

(b)
if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national securities exchange, the average
of the closing bid and asked prices on the date of determination as reported in The Wall Street Journal or such other source
as the Committee deems reliable; or

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 18

     

    

 

(c)
if none of the foregoing is applicable, by the Board or the Committee in good faith.

 

26.21.
“Insider” means an officer or director of Intiva or any other person whose transactions in Intiva’s
Common Stock are subject to Section 16 of the Exchange Act.

 

26.22.
“Intiva” means Intiva BioPharma Inc., a Delaware corporation, or any successor corporation.

 

26.23.
“IRS” means the United States Internal Revenue Service.

 

26.24.
“Non-Employee Director” means a Director who is not an Employee of Intiva or any Parent, Subsidiary
or Affiliate.

 

26.25.
“Option” means an award of an option to purchase Shares pursuant to Section 5.

 

26.26.
“Parent” means any corporation (other than Intiva) in an unbroken chain of corporations ending with
Intiva if each of such corporations other than Intiva owns stock possessing fifty percent (50%) or more of the total combined
voting power of all classes of stock in one of the other corporations in such chain.

 

26.27.
“Participant” means a person who holds an Award under this Plan.

 

26.28.
“Performance Factors” means any of the factors selected by the Committee and specified in an Award Agreement,
from among the following objective measures, either individually, alternatively or in any combination, applied to Intiva as a
whole or any business unit or Subsidiary, either individually, alternatively, or in any combination, on a GAAP or non-GAAP basis,
and measured, to the extent applicable on an absolute basis or relative to a pre-established target, to determine whether the
performance goals established by the Committee with respect to applicable Awards have been satisfied:

 

(a)
Profit Before Tax;

 

(b)
Billings;

 

(c)
Revenue;

 

(d)
Net revenue;

 

(e)
Earnings (which may include earnings before interest and taxes, earnings before taxes, net earnings, stock-based compensation
expenses, depreciation and amortization);

 

(f)
Operating income;

 

(g)
Operating margin;

 

(h)
Operating profit;

 

(i)
Controllable operating profit, or net operating profit;

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 19

     

    

 

(j)
Net Profit;

 

(k)
Gross margin;

 

(l)
Operating expenses or operating expenses as a percentage of revenue;

 

(m)
Net income;

 

(n)
Earnings per share;

 

(o)
Total stockholder return;

 

(p)
Market share;

 

(q)
Return on assets or net assets;

 

(r)
Intiva’s stock price;

 

(s)
Growth in stockholder value relative to a pre-determined index;

 

(t)
Return on equity;

 

(u)
Return on invested capital;

 

(v)
Cash Flow (including free cash flow or operating cash flows);

 

(w)
Cash conversion cycle;

 

(x)
Economic value added;

 

(y)
Individual confidential business objectives;

 

(z)
Contract awards or backlog;

 

(aa)
Overhead or other expense reduction;

 

(bb)
Credit rating;

 

(cc)
Strategic plan development and implementation;

 

(dd)
Succession plan development and implementation;

 

(ee)
Customer indicators and/or satisfaction;

 

(ff)
New product invention or innovation;

 

(gg)
Attainment of research and development milestones;

 

(hh)
Improvements in productivity;

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 20

     

    

 

(jj)
Attainment of objective operating goals and employee metrics;

 

(jj)
Sales;

 

(kk)
Expenses;

 

(ll)
Balance of cash, cash equivalents and marketable securities;

 

(mm)
Completion of an identified special project;

 

(nn)
Completion of a joint venture or other corporate transaction;

 

(oo)
Employee satisfaction and/or retention;

 

(pp)
Research and development expenses;

 

(qq)
Working capital targets and changes in working capital; and

 

(rr)
Any other metric that is capable of measurement as determined by the Committee.

 

The
Committee may, in recognition of unusual or non-recurring items such as acquisition-related activities or changes in applicable
accounting rules, provide for one or more equitable adjustments (based on objective standards) to the Performance Factors to preserve
the Committee’s original intent regarding the Performance Factors at the time of the initial award grant. It is within the
sole discretion of the Committee to make or not make any such equitable adjustments.

 

26.29.
“Performance Period” means one or more periods of time, which may be of varying and overlapping
durations, as the Committee may select, over which the attainment of one or more Performance Factors will be measured for the
purpose of determining a Participant’s right to, and the payment of, a Performance Award.

 

26.30.
“Permitted Transferee” means any child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law
(including adoptive relationships) of the Employee, any person sharing the Employee’s household (other than a tenant or
employee), a trust in which these persons (or the Employee) have more than 50% of the beneficial interest, a foundation in which
these persons (or the Employee) control the management of assets, and any other entity in which these persons (or the Employee)
own more than 50% of the voting interests.

 

26.31.
“Plan” means this Intiva BioPharma Inc. 2018 Equity Incentive Plan.

 

26.32.
“Purchase Price” means the price to be paid for Shares acquired under the Plan, other than Shares
acquired upon exercise of an Option or SAR.

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 21

     

    

 

26.33.
“Restricted Stock Award” means an award of Shares pursuant to Section 6 or Section 10
of the Plan, or issued pursuant to the early exercise of an Option.

 

26.34.
“SEC” means the United States Securities and Exchange Commission.

 

26.35.
“Securities Act” means the United States Securities Act of 1933, as amended.

 

26.36.
“Service” will mean service as an Employee, Consultant, Director or Non-Employee Director, to Intiva
or a Parent, Subsidiary or Affiliate, subject to such further limitations as may be set forth in the Plan or the applicable Award
Agreement. An Employee will not be deemed to have ceased to provide Service in the case of (a) sick leave, (b) military leave,
or (c) any other leave of absence approved by Intiva; provided, that such leave is for a period of not more than 90 days
unless reemployment upon the expiration of such leave is guaranteed by contract or statute. Notwithstanding anything to the contrary,
an Employee will not be deemed to have ceased to provide Service if a formal policy adopted from time to time by Intiva and issued
and promulgated to employees in writing provides otherwise. In the case of any Employee on an approved leave of absence or a reduction
in hours worked (for illustrative purposes only, a change in schedule from that of full-time to part-time), the Committee may
make such provisions respecting suspension or modification of vesting of the Award while on leave from the employ of Intiva or
a Parent, Subsidiary or Affiliate or during such change in working hours as it may deem appropriate, except that in no event may
an Award be exercised after the expiration of the term set forth in the applicable Award Agreement. In the event of military or
other protected leave, if required by applicable laws, vesting will continue for the longest period that vesting continues under
any other statutory or Intiva-approved leave of absence and, upon a Participant’s returning from military leave, he or she
will be given vesting credit with respect to Awards to the same extent as would have applied had the Participant continued to
provide Service to Intiva throughout the leave on the same terms as he or she was providing Service immediately prior to such
leave. An Employee will have terminated employment as of the date he or she ceases to provide Service (regardless of whether the
termination is in breach of local employment laws or is later found to be invalid) and employment will not be extended by any
notice period or garden leave mandated by local law, provided however, that a change in status from an Employee to a Consultant
or a Non-Employee Director (or vice versa) will not terminate a Participant’s Service, unless determined by the Committee,
in its discretion. The Committee will have sole discretion to determine whether a Participant has ceased to provide Service and
the effective date on which the Participant ceased to provide Service.

 

26.37.
“Shares” means shares of Intiva’s Common Stock and the common stock of any successor entity.

 

26.38.
“Stock Appreciation Right” means an Award granted pursuant to Section 8 or Section 10
of the Plan.

 

26.39.
“Stock Bonus” means an Award granted pursuant to Section 7 or Section 10 of the Plan.

 

26.40.
“Subsidiary” means any corporation (other than Intiva) in an unbroken chain of corporations beginning
with Intiva if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent
(50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

 

26.41.
“Treasury Regulations” means regulations promulgated by the United States Treasury Department.

 

26.42.
“Unvested Shares” means Shares that have not yet vested or are subject to a right of repurchase
in favor of Intiva (or any successor thereto).

 

    	Intiva BioPharma Inc. 2018 Equity Incentive Plan - Page 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]